

Published in final edited form as:

AIDS Care. 2021 June; 33(6): 767-785. doi:10.1080/09540121.2021.1874273.

# Results from Project GOLD: A pilot randomized controlled trial of a psychoeducational HIV/STI prevention intervention for Black youth

Bridgette M. Brawner, PhD, MDiv, APRN<sup>1,\*</sup>, Loretta Sweet Jemmott, PhD, FAAN, RN<sup>2</sup>, Alexandra L. Hanlon, PhD<sup>3</sup>, Alicia J. Lozano, MS<sup>4</sup>, Sarah Abboud, PhD, RN<sup>5</sup>, Charisse Ahmed, BSN, RN<sup>6</sup>, Gina Wingood, ScD<sup>7</sup>

<sup>1</sup>Department of Family and Community Health, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania, United States of America; Twitter: @DrBMBrawner https://twitter.com/DrBMBrawner; Facebook: Dr. Bridgette M. Brawner https://www.facebook.com/DrBMBrawner/; LinkedIn: Bridgette M. Brawner, PhD, MDiv, APRN https://www.linkedin.com/in/bridgette-m-brawner-phd-mdiv-aprn-754a24109/

<sup>2</sup>Department of Nursing, College of Nursing and Health Professions, Drexel University, Philadelphia, Pennsylvania, United States of America; Twitter: https://twitter.com/Dr\_SweetJ

<sup>3</sup>Center for Biostatistics and Health Data Science, Department of Statistics, College of Science, Virginia Tech, Roanoke, Virginia, United States of America; Twitter: @al\_hanlon https://twitter.com/al\_hanlon

<sup>4</sup>Center for Biostatistics and Health Data Science, Department of Statistics, College of Science, Virginia Tech, Roanoke, Virginia, United States of America; Twitter: @aliciajlozano https://twitter.com/aliciajlozano

<sup>5</sup>Department of Women, Children, and Family Health Science, University of Illinois at Chicago, College of Nursing, Chicago, Illinois, United States of America; Twitter: @SarahAbboud78 https://twitter.com/sarahabboud78

<sup>6</sup>Department of Family and Community Health, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania, United States of America; LinkedIn: https://www.linkedin.com/in/charisse-ahmed-2b341866/

<sup>7</sup>Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York, United States of America

#### **Abstract**

\*Corresponding author University of Pennsylvania School of Nursing, 418 Curie Blvd., 4th Floor, Room 419, Philadelphia, PA 19104-4217, 215-898-0715 (office), 215-746-3374 (fax), brawnerb@upenn.edu.

ClinicalTrials.gov Identifier: NCT03348813

https://clinicaltrials.gov/ct2/show/NCT03348813?

term = mental + health& recrs = e&type = Intr&cond = Hiv&titles = HIV%2FSTI + Prevention + Among + Black + Adolescents + With + Mental + Illnesses& rank = 1

Conflict of Interest/Disclosures: Drs. Brawner, Jemmott, Hanlon, Abboud and Wingood, and Ms. Lozano and Ms. Ahmed report no biomedical financial interests or potential conflicts of interest.

Black youth face significant disparities in HIV/sexually transmitted infection (STI) disease burden—statistics among heterosexual Black youth are concerning. Mental illness and emotion regulation are documented contributors to HIV/STI risk, yet the majority of HIV/STI prevention interventions do not address these factors. Project GOLD was a pilot randomized controlled trial of a psychoeducational HIV/STI prevention intervention designed to address the role of mental illness and emotion regulation in HIV/STI risk among heterosexually-active Black youth aged 14 to 17 (N = 108). Participants were recruited from outpatient mental health treatment programs and general community settings via community partner referrals, face-to-face encounters, flyers and social media. Assessments were conducted pretest, immediate posttest, and at 3-, 6-, and 12month follow-up. Although there were no statistically significant differences in behavior change from baseline, there were practically significant effect sizes among HIV condition participants when compared to the general health condition (e.g., increased proportion of condom use for vaginal sex at 3 months, fewer sexual partners at 6 months). An increase in theoretical mediators (e.g., condom use negotiation beliefs, pro-Black ethnic identity) was sustained at 12 months. HIV condition participants also reported lower depressive symptom severity, with statistical significance noted at immediate post and at 3 months. The findings highlight the importance and challenges of engaging Black youth in culturally and contextually relevant, developmentally and psychologically appropriate HIV/STI prevention interventions. Future work is needed to avoid unnecessary health complications in this demographic.

#### **Keywords**

Black; emotion regulation; HIV/STI; intervention; mental health

The HIV/sexually transmitted infection (STI) epidemic in the United States disproportionately affects Black youth. Compared to their White heterosexual counterparts, Black high school students are significantly more likely to initiate sexual activity before age 13 (7.5% vs. 2.1%, p<0.01) and have sex with four or more persons during their lives (14.8% vs. 8.6%, p<0.01) (Centers for Disease Control and Prevention [CDC], 2018c); this heightens their risk for HIV/STIs. While Syphilis and HIV are less prevalent than Chlamydia and Gonorrhea among heterosexual youth (CDC, 2018a; CDC, 2018b), they become more prominent in adulthood and have dire health consequences (e.g., congenital Syphilis, late AIDS diagnosis) (Tsevat et al., 2017). Moreover, antimicrobial resistance, a global concern, is making STIs more difficult to treat (Wi et al., 2017).

Areas such as Philadelphia, PA are hit particularly hard, with stark HIV disparities noted among heterosexual cases (Brawner et al, 2017; Philadelphia Department of Publich Health [PDPH], 2017a). In Philadelphia's predominantly Black public high schools, 6.1% of females and 2.4% of males tested positive for Chlamydia and/or Gonorrhea (PDPH, 2017b). One in five of the City's *total* Chlamydia cases were among females aged 15 to 19, with prevalence rates approaching 8,000 per 100,000 (PDPH, 2017b). Gonorrhea prevalence rates among males and females aged 15 to 19 exceed 1,000 per 100,000 (PDPH, 2017b). Compared to a national sample, Black youth in Philadelphia are significantly more likely to have ever drank alcohol, used drugs (e.g., synthetic marijuana), and not used condoms (CDC, 2016). Moreover, research documents alarming reports of sexual partner concurrency

(i.e., more than two in five participants reported having sex with more than one person in the same day) (Brawner et al., 2017). These are known contributors to rapid HIV/STI spread.

To contextualize these statistics—and avoid further marginalization/vilification of this key population—interactive effects across individual, social and structural domains must be acknowledged (Brawner, 2014). This includes recognizing that factors such as racism, discrimination and neighborhood disadvantage influence HIV/STI disease burden (Banks et al., 2020); multi-level interventions are needed to rectify these injustices (Auerbach, 2009; Hosek & Pettifor, 2019). While engaging in this macro-level work, racial/ethnic identity, gender role norms, mental illness and emotion regulation are readily modifiable mediators of HIV/STI risk-related sexual behaviors among Black youth. These factors influence HIV/STI risk as some youth engage in risk behaviors (e.g., condomless sex) to cope with feelings such as sadness and/or inferiority (Brawner et al., 2017; Donenberg et al., 2012; Foley et al., 2019; Lanier et al., 2017; Tull et al., 2012; Weiss et al., 2019). Targeting these mediators (e.g., bolstering pro-Black identity, regulating emotions) can reduce HIV/STI risk, yet limited interventions exist to address affective components of the sexual decision-making process.

Multisession (Salam et al., 2016; Scott-Sheldon et al., 2011) and single session (Crosby et al., 2019; Dolcini et al., 2010) interventions have effectively increased condom use, decreased the number of sexual partners and reduced incident STIs among Black youth (Goesling et al., 2014). In fact, 29 evidence-based HIV prevention interventions have been packaged for national dissemination. However, barriers to implementation (e.g., cost, time) have hindered some of these programs from achieving maximal impact, and HIV/STI incidence and prevalence rates among Black youth remain high. Further, an international systematic review highlights the paucity of HIV/STI prevention interventions that address the role of mental illness and emotion regulation in sexual risk behaviors (Salam et al., 2016). Some of the interventions that incorporate affect management have decreased sexual activity and HIV transmission myths, and increased consistent condom use and self-efficacy (Brown et al., 2014; Brown et al., 2017; Houck et al., 2018). These interventions are delivered either as family-based (Brown et al., 2014; Esposito-Smythers et al., 2017) or youth-only models (Brown et al., 2017; Houck et al., 2018). Most of these existing studies, however, include predominantly non-Black samples, have small sample sizes, or are not tailored to address key socio-structural factors that contribute to psychological distress and risk behaviors among Black youth.

To fill this gap, "Project GOLD: We are Kings and Queens" was a pilot randomized controlled trial of a psychoeducational HIV/STI prevention intervention designed to address the role of mental illness and emotion regulation in HIV/STI risk among heterosexually-active Black youth aged 14 to 17 (*N*=108). This paper reports results from the 12-month trial alongside research challenges to facilitate engagement of this demographic in HIV/STI prevention work. The long-term goal is to enhance culturally and contextually relevant, developmentally and psychologically appropriate sexual health promotion programs for Black youth.

## **Materials and Methods**

Institutional Review Boards at the first author's home institution, health department and school district approved the study. Participants provided written informed consent, without the requirement of a parental permission waiver; non-affiliated youth legal experts deemed they met legal age of consent criteria for the research procedures (Brawner & Sutton, 2018). The trial ran from August 2014 to December 2016; see (Brawner et al., 2019a and Brawner et al., 2019b) for the intervention development process and study protocol. All research activities took place at the first author's institution. Due to delays and accrual difficulties, the protocol was expanded to include youth in the general community (n=58, 54%), in addition to those who were currently receiving outpatient mental health treatment (n=50, 46%).

All participants were recruited from outpatient mental health treatment programs or general community settings via community partner referrals, face-to-face encounters, flyers and social media. Those who were recruited from public areas (e.g., parks, community events) and self-reported that they were not currently receiving mental health treatment at the time of screening were labeled as general community participants in the dataset. Those who were recruited from outpatient mental health treatment programs or self-reported currently receiving mental health treatment were labeled as in treatment participants. After initial screening for preliminary eligibility, participants underwent an interviewer-administered structured clinical interview using the MINI International Neuropsychiatric Inventory (van Vliet & de Beurs, 2007) to determine mental health diagnoses and rule out exclusionary conditions (e.g., active psychosis, schizophrenia). The most frequent diagnoses were substance use disorders (15%), obsessive compulsive disorder (7%) and post-traumatic stress disorder (6%) (Opara et al., 2021).

The permuted-block randomization technique was used with a block size of 4 and a 1:1 allocation ratio. ALH (biostatistician) generated the randomization list using a pseudorandomizer computer program. The Research Coordinator implemented the treatment allocation protocol; the investigators were blinded. To reduce the risk of encountering a floor or ceiling effect with intervention responsiveness, participants were stratified based on their Patient Health Questionnaire (PHQ-9) total scores (none/moderate depression versus moderately severe/severe depression) and gender.

Participants were randomized to either the HIV/STI prevention intervention or the general health control condition (i.e., diet, exercise). The 2-day (3 hours/day) intervention drew from psychology (Beck, 2011; Gross, 2015), developmental and behavior change theories (Azjen, 1991), and was embedded in a social determinants of health framework (Dean & Fenton, 2010). Content on emotion regulation (e.g., meditation skills) was included in both intervention conditions as it related to general life (e.g., identifying triggers) and sexual decision-making (HIV only; e.g., alternatives to using sex as a coping strategy). As a result, the intervention addresses the way one's emotions (e.g., anger, sadness) affect decisions about sex. Activities were also threaded throughout the curriculum to highlight social determinants of sexual behaviors such as financial independence and stability, navigating parental conflict and residential instability, and dealing with daily stressors such as racism. Booster sessions were not included to promote feasibility if integrated into programs with

limited resources. Facilitators underwent 16 hours of training for their respective study arms and rated activity adherence after each session; reported fidelity was 98%.

The design included pretest, immediate posttest, and 3-, 6-, and 12-month follow-up assessments. With the study's fixed end date of December 2016, many participants were only scheduled to complete the 3-month follow-up. At the baseline and follow-up assessments, participants completed a computer-assisted personal interview (CAPI) with questions on sociodemographics, sexual behaviors, and theoretical mediators of HIV/STI risk. They were also tested for HIV (oral swab), and Chlamydia and Gonorrhea (urine sample).

Past 30-day alcohol and marijuana use were measured in response to the question, "In the past 30 days, on average how many days did you use [alcohol/marijuana]"? Response options ranged from 1 (never) to 10 (5 or more times per day). Attitudes toward condom use (e.g., condom use hedonistic beliefs) were measured using validated scales from our previous research and included 5-point Likert response options ranging from 1 (strongly disagree) to 5 (strongly agree) (Ordinal Cronbach's  $\alpha = 0.54$  to 0.90); all reported Cronbach's a are from this study's sample. The Children's Emotion Management Scale (CEMS)(Zeman et al., 2001) was used to assess self-reported sadness and anger management on a 3-point Likert scale of 1 (hardly ever) to 3 (often). The instrument includes subscales of inhibition, dysregulation and coping, with higher values indicating more of each construct (ordinal Cronbach's  $\alpha = 0.63-0.87$ ). Ethnic identity was assessed using the revised Adolescent Survey of Black Life (ASBL)(Resnicow et al., 1999) which measures: 1) attitudes about being Black, 2) attitudes toward Whites, and 3) perceptions of racism. Items were scored on a 4-point Likert scale ranging from 1 (agree a lot) to 4 (disagree a lot). Higher values indicate higher levels of the construct (ordinal Cronbach's  $\alpha = 0.68-0.91$ ). Gender role norms were measured using The Attitudes Toward Women Scale for Adolescents (ATWSA) (Galambos et al., 1985). Responses are rated on a 4-point Likert scale, 1 (strongly disagree) to 4 (strongly agree), to assess participants' attitudes of adolescents toward gender roles (e.g. women's rights and roles compared to men's; ordinal Cronbach's  $\alpha = 0.81$ ). HIV/STI knowledge was measured using true/false items with myths and facts about HIV/STI transmission (e.g., "using Vaseline as a lubricant when having sex lowers the chance of getting STIs and HIV/AIDS"); higher scores indicate more HIV/STI knowledge (Cronbach's  $\alpha = 0.82$ ) (Koniak-Griffin & Brecht, 1995). The PHQ-9, a depression screening tool (Kroenke et al., 2001), was used to assess depressive symptom severity. Items were rated from 0 (not at all) to 3 (nearly every day), with higher scores reflecting greater symptom severity (ordinal Cronbach's  $\alpha = 0.82$ ).

The primary outcome was proportion of condom use for vaginal sex; the secondary outcome was number of sexual partners. Both the primary and secondary outcomes were measured as past 3 months self-reported behavior. Given high reports of sexual partner concurrency, we estimated the effect of the intervention on whether participants had sex with more than one person in the same day, month or while already in a sexual relationship. Effects on theoretical mediators (e.g., condom use beliefs) were also estimated. The number of positive HIV/STI cases was too small to include in effect estimations.

For the analyses, descriptive statistics were used to characterize the study variables at each time point, and their changes from baseline by intervention condition. Since all continuous variables were not normally distributed, non-parametric exact Wilcoxon rank-sum tests were used to examine differences in rank sum scores across the two conditions. Comparisons of categorical variables relied on Fisher's exact tests. We hypothesized that compared to the general health group, participants in the HIV intervention group would have an increased proportion of condom use for vaginal sex, fewer sexual partners and an increase in mediators purported to reduce sexual risk behaviors (e.g., condom use negotiation beliefs). As this was a small pilot study, the focus was on estimation of effect and not formal hypothesis testing. Effect sizes were based on  $\eta$ 2 (eta-squared) for continuous variables (small [0.01], medium [0.06], and large [>0.14]) and Cramer's V for categorical variables (small [0.10-0.29], medium [0.30-0.50], and large [>0.50]). Statistical significance was taken at the 0.05 level, and did not adjust for multiplicity given the pilot nature of this study. Reporting effect sizes to supplement p-values is recommended in intervention research due to potential differences between statistical and practical significance (Sun et al., 2010). All analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC). Pairwise deletion (available-case analysis) was used to handle missing data.

The original intent was to examine change in the study outcomes from baseline to 12 months. However, with the study delays and fixed end date, the majority of participants could only be scheduled for the 3-month follow-up. For post-hoc power analysis, the primary research comparison was change from baseline to 3 months in proportion of condom use for vaginal sex (primary outcome) across the HIV intervention and general health groups. Observed mean changes in proportion of condom use for vaginal sex for the two groups were 0.21 (HIV intervention) versus -0.02 (general health). For group sample sizes of 16 and 13 with complete data for the primary outcome at both timepoints, respectively, this study had 9% power to detect a mean difference of 0.23 in changes in proportion of condom use at 3 months using a two-sided, Wilcoxon rank-sum test and a type 1 error rate (alpha) of 0.05. Of note, the actual comparison did not demonstrate a statistically significant difference, with p=0.20.

# Results

See Figure 1 for the Consolidated Standards of Reporting Trials (CONSORT) diagram. Most (89%) of those eligible to participate enrolled in the study; 45 participants were lost to follow-up after screening. After randomization, one participant did not receive the intervention and was connected to care in accordance with the study's suicide risk assessment protocol for suicidality at the baseline visit. Completion (attendance both intervention days) was approximately 90% in both conditions, with no statistically significant differences between conditions. Attrition across the follow-up periods ranged from 17%-42%. Tables 1, 2 and 3 detail the reasons for missing data at each time point and sample characteristics according to dropout status. Those who dropped out were slightly younger (*M*=15.5 vs. 16, *p*=0.0052; see Table 3). The predominant causes were lost to follow-up, placement in residential treatment, incarceration and withdrawal. Of the three withdrawn participants, two were at the request of participants, and one was a parent request. Sadly, one participant died from unrelated gun violence.

At baseline, participants were 15.78 years old (SD=0.97), mostly male (62%), used condoms 66% of the time for vaginal sex (SD=0.40) and had 3 sexual partners in the past 3 months (SD=3.79). Compared to HIV participants (see Table 4), general health participants had statistically significantly more: sexual partners in the past 3 months (Median=2 vs. 1, p=0.04,  $\eta^2$ =0.04), same month sexual partner concurrency (57% vs. 35%, p=0.02, Cramer's V=0.23) and past 30-day alcohol use (Median=2 [1 to 3 times last month] vs. 1 [never], p=0.01,  $\eta^2$ =0.13). These participants also reported a practically significant difference in past 30-day marijuana use (Median=3 [1 to 2 times per week] vs. Median=2 [1 to 3 times last month], p=0.15,  $\eta^2$ =0.04).

Means are reported below for readability; however, the non-parametric analyses were based on comparisons of the medians. There were no statistically significant differences observed in behavior change from baseline. However, there were multiple variables with practically significant effect sizes (see Table 5). At 3 months, compared to general health participants, HIV participants had an increased proportion of condom use for vaginal sex (77% vs. 64%, Mean change [M]=0.21 vs. -0.02, p=0.20,  $\eta^2$ =0.06). At 6 months, HIV participants had fewer sexual partners (M=1 vs. 1.67, M=-0.54 vs. -0.57, p=0.24,  $\eta^2=0.05$ ), less same day sexual partner concurrency (6% vs. 33%, p=0.08, V=0.41) and increased anger coping  $(M=2.47 \text{ vs. } 2.24, M=0.28 \text{ vs. } 0.06, p=0.15, \eta^2=0.06)$ . An increase in several mediators was sustained at 12 months among HIV participants including condom use prevention beliefs (M=4.55 vs. 4.28, M =0.61 vs. 0, p=0.36,  $\eta^2$ =0.04), condom use negotiation beliefs  $(M=4.55 \text{ vs. } 4.22, M=0 \text{ vs. } -0.04, p=0.32, \eta^2=0.05)$ , condom use self-efficacy  $(M=4.40 \text{ vs. } -0.04, p=0.32, \eta^2=0.05)$ 4.15, M = 0.11 vs. 0.02, p=0.22,  $\eta^2$ =0.07), pro-Black ethnic identity (M=3.55 vs. 3.46, M =0.14 vs. 0.23, p=0.69,  $\eta^2$ =0.01) and HIV/STI knowledge (M=0.77 vs. 0.70, M = 0.06 vs. 0.09, p=0.35,  $\eta^2$ =0.04). HIV participants also reported lower depressive symptom severity, with statistical significance noted from baseline at immediate post (M=2.19 vs. 2.80, M=1.00-1.06 vs. 0.10, p=0.01,  $\eta^2$ =0.07) and 3 months (M=2.82 vs. 4.24, M = -0.37 vs. 1.42, p=0.048,  $\eta^2$ =0.06). Participants in both conditions also experienced a practically significant decrease in past 30-day alcohol and marijuana use.

## **Discussion**

Despite the well-documented role of mental illness and emotion regulation in youth risk behaviors, a paucity of HIV/STI prevention interventions incorporate these factors. Project GOLD was designed to address this gap, merging advances in HIV/STI prevention science with evidence-based psychological practices (e.g., emotional expression). Reporting of clinical trial results—including null effects—is key to research rigor, and these findings advance the science. While the small pilot was not powered to demonstrate a *statistically* significant effect on condom use or number of sexual partners, there were *practically* significant changes worth noting. Compared to general health participants, HIV participants reported 13% more condom use for vaginal sex at 3 months, fewer sexual partners and 27% less same day sexual partner concurrency at 6 months, and an increase in key mediators of sexual behaviors (e.g., condom use negotiation beliefs, pro-Black ethnic identity) that was sustained at 12 months. These clinically meaningful signals of the intervention's utility are comparable to findings from previous HIV prevention interventions that showed similar changes (Dolcini et al., 2010; Houck et al., 2018; Scott-Sheldon et al., 2011). Further, the

findings give insight into attitudes, psychological symptoms and behaviors over time, which can be used to promote sexual health among Black youth.

It is critical that behavioral HIV/STI prevention interventions are prioritized for heterosexually-active Black youth, delivered in a culturally and contextually congruent manner and include modules on the role of mood and emotion regulation in safer sexual behaviors. A group behavioral intervention targeted emotion regulation and demonstrated delayed vaginal intercourse and increased condom use, with a sustained effect 2.5 years post-intervention (Houck et al., 2018). This emphasizes the importance and potential impact of such work. Technological advances can also be leveraged to meet youth where they are, factoring in novel experiences through simulation and social media. As an example, researchers have demonstrated preliminary feasibility, acceptability and impact on enhancing emotion regulation in risky situations by pairing immersive virtual reality environments with an emotion regulation and risk reduction intervention (Hadley et al., 2018). Others have also noted the relevance of social media in delivering sexual health messages, promoting the use of online platforms to mitigate risk behaviors (Stevens et al., 2017; Stevens et al., 2020).

Regarding challenges, although the research team gathered extensive contact information from participants, the majority of those lost to follow up had unstable contact information and could not be located. This alongside the case of suicidality, number of participants incarcerated and placed in residential treatment, and the victim of gun violence speak to the high psychiatric acuity and adversities faced by the study population. Moreover, those who completed the intervention faced difficulties with work schedules, childcare (for their own children and/or those of relatives) and transportation. The partnering mental health treatment programs also struggled to engage Black youth in care. Altogether, this hindered potential enrollment, further reducing the already small sample size, but more importantly, amplifies systemic issues faced by Black youth. As others work with this demographic, it will be important to consider these factors and strategize ways to better meet their needs. Such research should be a public health priority for Black youth given that: 1) Black females aged 15 to 19 have the highest risk of repeat Chlamydial infections (44%) compared to women of other ages and racial/ethnic groups (Cha et al., 2019), and 2) factors such as depressive symptoms have been documented to affect condom use self-efficacy, condomless sex and number of sexual partners over time (Foley et al., 2019).

The study limitations must be acknowledged. The sample was small, the fixed end date meant fewer participants completed the 6- and 12-month follow-ups, and there was considerable attrition. This reduced power for the behavioral outcomes, limited detection of effects and increases uncertainty in the findings. The outcomes were self-reported and thus susceptible to bias; participants did undergo HIV/STI testing but there were too few cases to include in the analyses. The intent was to test an intervention for youth experiencing mental illness and emotion regulation, yet depressive symptoms were low in the sample—PHQ-9 scores less than four indicate minimal depression. However, depressive symptoms were only one of many symptoms participants experienced (e.g., anxiety) and they reported difficulties regulating anger and sadness, thus the overall objective was still achieved. Given that the intervention demonstrated practically significant findings that are comparable to previous

results of successful HIV prevention interventions, it should be tested in a fully powered trial for final determinations. The results contribute to the literature, highlighting a novel intervention that was successfully implemented with a group at increased risk for HIV/STIs.

Comprehensive behavioral interventions that include nontraditional targets (e.g., emotion regulation) may decrease HIV/STI risk and help Black youth address mediating factors (e.g., psychological distress) that affect their health. Project GOLD was developed to advance the science in this area, and requires subsequent evaluation in a larger sample. Given the severity of HIV/STIs, strategies are needed now more than ever to engage Black youth in sexual health promotion to prevent future complications.

# **Acknowledgements:**

This research was funded by the Centers for Disease Control and Prevention (Minority AIDS Research Initiative) grant # U01PS003304 awarded to Dr. Bridgette M. Brawner. The research was also supported by a grant from the Penn Mental Health AIDS Research Center (PMHARC), a National Institutes of Health-funded program (P30MH097488), to Dr. Brawner. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the National Institutes of Health. The authors are grateful to the study participants, and thank the Made Aware with Care (MAC) research team and youth community advisory board for their assistance with the study.

# **Data Availability Statement:**

The data that support the findings of this study are available on request from the corresponding author, BMB. The data are not publicly available due to information that could compromise the privacy of research participants.

#### References


- Auerbach J (2009). Transforming social structures and environments to help in HIV prevention. Health Affairs, 28(6), 1655–1665. 10.1377/hlthaff.28.6.1655 [PubMed: 19887406]
- Azjen I (1991). The Theory of Planned Behavior. Organizational Behavior and Human Decision Processes, 50, 179–211.
- Banks DE, Hensel DJ, & Zapolski TC (2020). Integrating individual and contextual factors to explain disparities in HIV/STI among heterosexual African American youth: A contemporary literature review and social ecological model. Archives of sexual behavior, *epub ahead of print*.
- Beck JS (2011). Cognitive Behavior Therapy: Basics and Beyond (Second ed.). Guilford Press.
- Brawner BM (2014). A multilevel understanding of HIV/AIDS disease burden among African American women. Journal of Obstetric, Gynecologic, and Neonatal Nursing, 43(5), 633–643. 10.1111/1552-6909.12481
- Brawner BM, Guthrie B, Stevens R, Taylor L, Eberhart M, & Schensul JJ (2017). Place still matters: Racial/ethnic and geographic disparities in HIV transmission and disease burden. Journal of Urban Health, 94, 716–729. 10.1007/s11524-017-0198-2 [PubMed: 28879489]
- Brawner BM, Jemmott LS, Wingood G, Reason J, Daly B, Brooks K, & Lanier Y (2017). Feelings matter: Depression severity and emotion regulation in HIV/STI risk-related sexual behaviors. Journal of Child and Family Studies, 26(6), 1635–1645. 10.1007/s10826-017-0674-z
- Brown LK, Hadley W, Donenberg GR, DiClemente RJ, Lescano C, Lang DM, Crosby R, Barker D, & Oster D (2014). Project STYLE: A multisite RCT for HIV prevention among youths in mental health treatment. Psychiatric Services, 65(3), 338–344. 10.1176/appi.ps.201300095 [PubMed: 24382603]
- Brown LK, Whiteley L, Houck CD, Craker LK, Lowery A, Beausoleil N, & Donenberg G (2017). The role of affect management for HIV risk reduction for youth in alternative schools. Journal of the American Academy of Child & Adolescent Psychiatry, 56(6), 524–531. [PubMed: 28545758]

Centers for Disease Control and Prevention. (2016). Youth Risk Behavior Surveillance — United States, 2015. Morbidity and Mortality Weekly Report, 65(6). https://www.cdc.gov/mmwr/volumes/65/ss/pdfs/ss6506.pdf

- Centers for Disease Control and Prevention. (2018a). HIV Surveillance Report: Diagnoses of HIV Infection in the United States and Dependent Areas, 2018. Retrieved 6 25, 2020 from https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-preliminary-vol-30.pdf
- Centers for Disease Control and Prevention. (2018b). Sexually Transmitted Disease Surveillance 2017: STDs in Adolescents and Young Adults. Retrieved 6 25, 2020 from https://www.cdc.gov/std/stats17/adolescents.htm
- Centers for Disease Control and Prevention. (2018c). United States, High School Youth Risk Behavior Survey, 2017. Retrieved 6 25, 2020 from https://nccd.cdc.gov/youthonline/App/Results.aspx?
- Cha S, Newman DR, Rahman M, & Peterman TA (2019). High rates of repeat chlamydial infections among young women—Louisiana, 2000–2015. Sexually Transmitted Diseases, 46(1), 52–57. 10.1097/olq.0000000000000006 [PubMed: 30148756]
- Crosby RA, Mena L, & Smith RV (2019). Randomised controlled trial of a brief, clinic-based intervention to promote safer sex among young Black men who have sex with men: implications for pre-exposure prophylaxis-related counselling. Sexual health, 16(2), 187–191. [PubMed: 30721647]
- Dean HD, & Fenton KA (2010). Addressing social determinants of health in the prevention and control of HIV/AIDS, viral hepatitis, sexually transmitted infections, and tuberculosis. Public Health Reports, 125(Supplement 4), 1–5.
- Dolcini MM, Harper GW, Boyer CB, & Pollack LM (2010). Project ORE: A friendship-based intervention to prevent HIV/STI in urban African American adolescent females. Health Education & Behavior, 37(1), 115–132. [PubMed: 19535612]
- Donenberg GR, Emerson E, Brown LK, Houck C, & Mackesy-Amiti ME (2012). Sexual experience among emotionally and behaviorally disordered students in therapeutic day schools: An ecological examination of adolescent risk. Journal of Pediatric Psychology, 37(8), 904–913. 10.1093/jpepsy/jss056 [PubMed: 22467883]
- Esposito-Smythers C, Hadley W, Curby TW, & Brown LK (2017). Randomized pilot trial of a cognitive-behavioral alcohol, self-harm, and HIV prevention program for teens in mental health treatment. Behaviour research and therapy, 89, 49–56. [PubMed: 27883927]
- Foley JD, Vanable PA, Brown LK, Carey MP, DiClemente RJ, Romer D, & Valois RF (2019). Depressive symptoms as a longitudinal predictor of sexual risk behaviors among African-American adolescents. Health Psychology, 38(11), 1001–1009. 10.1037/hea0000780 [PubMed: 31380687]
- Galambos NL, Petersen AC, Richards M, & Gitelson IB (1985). The Attitudes Toward Women Scale for Adolescents (AWSA): A study of reliability and validity. Sex roles, 13(5-6), 343–356.
- Goesling B, Colman S, Trenholm C, Terzian M, & Moore K (2014). Programs to reduce teen pregnancy, sexually transmitted infections, and associated sexual risk behaviors: A systematic review. Journal of Adolescent Health, 54(5), 499–507.
- Gross JJ (2015). Emotion regulation: Current status and future prospects. Psychological Inquiry, 26(1), 1–26. 10.1080/1047840X.2014.940781
- Hadley W, Houck C, Brown LK, Spitalnick JS, Ferrer M, & Barker D (2018). Moving beyond role-play: Evaluating the use of virtual reality to teach emotion regulation for the prevention of adolescent risk behavior within a randomized pilot trial. Journal of Pediatric Psychology, 44(4), 425–435. 10.1093/jpepsy/jsy092
- Hosek S, & Pettifor A (2019). HIV prevention interventions for adolescents. Current HIV/AIDS Reports, 16(1), 120-128. 10.1007/s11904-019-00431-y [PubMed: 30707399]
- Houck CD, Barker DH, Hadley W, Menefee M, & Brown LK (2018). Sexual risk outcomes of an emotion regulation intervention for at-risk early adolescents. Pediatrics, 141(6), e20172525. [PubMed: 29748192]

Koniak-Griffin D, & Brecht ML (1995). Linkages between sexual risk taking, substance use, and AIDS knowledge among pregnant adolescents and young mothers. Nursing research, 44(6), 340–346. 10.1097/00006199-199511000-00004 [PubMed: 7501487]

- Kroenke K, Spitzer RL, & Williams JBW (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. 10.1046/j.1525-1497.2001.016009606.x [PubMed: 11556941]
- Lanier Y, Sommers MS, Fletcher J, Sutton MY, & Roberts DD (2017). Examining racial discrimination frequency, racial discrimination stress, and psychological well-being among Black early adolescents. Journal of Black Psychology, 43(3), 219–229. 10.1177/0095798416638189
- Philadelphia Department of Public Health. (2017a). AIDS Activities Coordinating Office Surveillance Report, 2016. City of Philadelphia. Retrieved 6 25, 2020 from https://www.phila.gov/media/20181002083053/HIV\_in\_Philadelphia\_2016.pdf
- Philadelphia Department of Public Health. (2017b). Annual Report. Division of Disease Control. Retrieved 6 25, 2020 from https://hip.phila.gov/Portals/\_default/HIP/DataReports/AnnualReports/PDPH\_Annual\_Report\_2017.pdf
- Resnicow K, Soler RE, Braithwaite RL, Selassie MB, & Smith M (1999). Development of a racial and ethnic identity scale for African American adolescents: The Survey of Black Life. Journal of Black Psychology, 25(2), 171–188.
- Salam RA, Faqqah A, Sajjad N, Lassi ZS, Das JK, Kaufman M, & Bhutta ZA (2016). Improving adolescent sexual and reproductive health: A systematic review of potential interventions. Journal of Adolescent Health, 59(4), S11–S28.
- Scott-Sheldon LA, Huedo-Medina TB, Warren MR, Johnson BT, & Carey MP (2011). Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: A meta-analysis, 1991 to 2010. Journal of Acquired Immune Deficiency Syndromes, 58(5), 489–498. [PubMed: 22083038]
- Stevens R, Gilliard-Matthews S, Dunaev J, Todhunter-Reid A, Brawner B, & Stewart J (2017). Social media use and sexual risk reduction behavior among minority youth: Seeking safe sex information. Nursing research, 66(5), 368–377. [PubMed: 28858145]
- Stevens RC, Brawner BM, Kranzler E, Giorgi S, Lazarus E, Abera M, Huang S, & Ungar L (2020). Exploring substance use tweets of youth in the United States: Mixed methods study. JMIR Public Health Surveillance, 6(1), e16191. 10.2196/16191 [PubMed: 32213472]
- Sun S, Pan W, & Wang LL (2010). A comprehensive review of effect size reporting and interpreting practices in academic journals in education and psychology. Journal of Educational Psychology, 102(4), 989–1004. 10.1037/a0019507
- Tsevat DG, Wiesenfeld HC, Parks C, & Peipert JF (2017). Sexually transmitted diseases and infertility. American Journal of Obstetrics and Gynecology, 216(1), 1–9. [PubMed: 28007229]
- Tull MT, Weiss NH, Adams CE, & Gratz KL (2012). The contribution of emotion regulation difficulties to risky sexual behavior within a sample of patients in residential substance abuse treatment. Addictive Behaviors, 37(10), 1084–1092. [PubMed: 22658304]
- van Vliet IM, & de Beurs E (2007). The MINI-International Neuropsychiatric Interview: A brief structured diagnostic psychiatric interview for DSM-IV en ICD-10 psychiatric disorders. Tijdschrift voor psychiatrie, 49(6), 393–397. http://europepmc.org/abstract/MED/17614093 [PubMed: 17614093]
- Weiss NH, Walsh K, DiLillo DD, Messman-Moore TL, & Gratz KL (2019). A longitudinal examination of posttraumatic stress disorder symptoms and risky sexual behavior: Evaluating emotion dysregulation dimensions as mediators. Archives of sexual behavior, 48(3), 975–986. [PubMed: 30771054]
- Wi T, Lahra MM, Ndowa F, Bala M, Dillon J-AR, Ramon-Pardo P, Eremin SR, Bolan G, & Unemo M (2017). Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS medicine, 14(7), e1002344. [PubMed: 28686231]
- Zeman J, Shipman K, & Penza-Clyve S (2001). Development and initial validation of the Children's Sadness Management Scale. Journal of Nonverbal Behavior, 25(3), 187–205.



**Figure 1.** Consolidated Standards of Reporting Trials (CONSORT) diagram. <sup>a</sup>Completion was defined as attending intervention Day 1 and Day 2. <sup>b</sup>The study's fixed end date was December 2016 thus all participants who completed the intervention were due to complete the immediate post and 3-month follow-ups; however, not all participants were due for the 6- and 12-month follow-ups. Numbers reflect those who were due to (denominator) and actually (numerator) completed their assigned follow-ups.

Table 1.

**Author Manuscript** 

**Author Manuscript** 

Partners

Baseli   Sex   25,   46,   57,   11,   53,   3,   40,   7,   7,   7,   7,   7,   7,   7,   7		Tin	Time Point		
; and used condoms	3-Month ne FU		6-Month FU	12-Month FU	Total
s had vaginal sex and used condoms					
s had vaginal sex and used condoms					
s had vaginal sex and used condoms					
s had vaginal sex and used condoms					
s had vaginal sex and used condoms					
sex and used condoms	30	21	6	5	65
sex and used condoms		17.80	7.63	4.24	55.08
sex and used condoms		32.31	13.85	7.69	
sex and used condoms		55.26	52.94	45.45	
	14	7	8	2	26
		5.93	2.54	1.69	22.03
		26.92	11.54	7.69	
		18.42	17.65	18.18	
	4	3	2	1	10
	3.39	2.54	1.69	0.85	8.47
		30.00	20.00	10.00	
		7.89	11.76	60.6	
25	3	3	0	1	7
42.8		2.54	0.00	0.85	5.93
		42.86	0.00	14.29	
	5.77	7.89	0.00	60.6	
Sexually active but provided zeroes for # times had sex and # times used condoms	0	4	8	2	6
0.0	0.00	3.39	2.54	1.69	7.63
0.0	0.00	44.44	33.33	22.22	
0.0	0.00	10.53	17.65	18.18	

Reason			Time Point		
	Baseline	3-Month $FU$	6-Month $FU$	12-Month FU	Total
Unable to calculate: Zero in denominator		0	0	0	1
	0.85	0.00	0.00	0.00	0.85
	100.00	0.00	0.00	0.00	
	1.92	0.00	0.00	0.00	
Total	52	38	17	111	118
	44.07	32.20	14.41	9.32	100.00
Number of Sexual Partners					
Did not provide information for # of partners	5	3	2	0	10
	4.24	2.54	1.69	0.00	8.47
	50.00	30.00	20.00	0.00	
	9.62	7.89	11.76	0.00	
Had complete information	46	34	13	111	104
	38.98	28.81	11.02	9.32	88.14
	44.23	32.69	12.50	10.58	
	88.46	89.47	76.47	100.00	
Not sexually active	1	1	2	0	4
	0.85	0.85	1.69	0.00	3.39
	25.00	25.00	50.00	0.00	
	1.92	2.63	11.76	0.00	
Total	52	38	17	111	118
	44.07	32.20	14.41	9.32	100.00

**Author Manuscript** 

Table 2.

**Author Manuscript** 

**Author Manuscript** 

artners Des (Ge

Descriptive Statistics on Reasons for Missing Data at Each Time Point for Proportion of Condom Use for Vaginal Sex and Number of Sexual Par (General Health condition).	Point for	r Proporti	on of Co	ndom Use	for Vagi
Reason		•	Time Point		
	Baseline	3-Month $FU$	6-Month $FU$	12-Month FU	Total
Proportion of Condom use for Vaginal Sex					
И					
%					
Row %					
Column %					
Had complete information	36	20	12	6	77
	29.03	16.13	89.6	7.26	62.10
	46.75	25.97	15.58	11.69	
	64.29	60.61	54.55	69.23	
Incomplete data for # times had vaginal sex and used condoms	10	10	7	33	30
	8.06	8.06	5.65	2.42	24.19
	33.33	33.33	23.33	10.00	
	17.86	30.30	31.82	23.08	
Not sexually active	1	1	1	0	33
	0.81	0.81	0.81	0.00	2.42
	33.33	33.33	33.33	0.00	
	1.79	3.03	4.55	0.00	
Reported more # times used condoms than # times had vaginal sex	S	1	0	1	7
	4.03	0.81	0.00	0.81	5.65
	71.43	14.29	0.00	14.29	
	8.93	3.03	0.00	69.7	
Sexually active but provided zeroes for # times had sex and # times used condoms	3	-	2	0	9
	2.42	0.81	1.61	0.00	4.84
	50.00	16.67	33.33	0.00	
	5.36	3.03	60.6	0.00	

Reason			Time Point		
	Baseline	3-Month $FU$	6-Month FU	12-Month FU	Total
Unable to calculate: Zero in denominator	1	0	0	0	1
	0.81	0.00	0.00	0.00	0.81
	100.00	0.00	0.00	0.00	
	1.79	0.00	0.00	0.00	
Total	56	33	22	13	124
	45.16	26.61	17.74	10.48	100.00
Number of Sexual Partners					
n					
%					
Row %					
Column %					
Did not provide information for # of partners	4	7	9	2	19
	3.23	5.65	4.84	1.61	15.32
	21.05	36.84	31.58	10.53	
	7.14	21.21	27.27	15.38	
Had complete information	51	24	15	111	101
	41.13	19.35	12.10	8.87	81.45
	50.50	23.76	14.85	10.89	
	91.07	72.73	68.18	84.62	
Not sexually active	1	2	1	0	4
	0.81	1.61	0.81	0.00	3.23
	25.00	50.00	25.00	0.00	
	1.79	90.9	4.55	0.00	
Total	99	33	22	13	124
	45.16	26.61	17.74	10.48	100.00

Table 3. Baseline sample characteristics according to dropout status (N= 108)

	0 40	Dropou	t Status		Effect
Characteristic	Overall Sample (N = 108)	$\begin{array}{c} \textbf{Dropped} \\ (N=46) \end{array}$	Retained (N = 62)	P-value <sup>1</sup>	Size <sup>2</sup>
Intervention Condition [n (%)]				0.6548	0.04
HIV	52 (48.2%)	21 (45.7%)	31 (50.0%)		
GH	56 (51.8%)	25 (54.3%)	31 (50.0%)		
Age [Mean (SD)]	15.78 (0.97)	15.48 (0.96)	16.00 (0.92)	0.0052	0.56
Gender [n (%)]				0.3233	0.10
Male	67 (62.0%)	31 (67.4%)	36 (58.1%)		
Female	41 (38.0%)	15 (32.6%)	26 (41.9%)		
Living Status [n (%)]				0.3578	0.21
In a house that my parent/guardian owns	50 (46.3%)	21 (45.6%)	29 (46.8%)		
In a house that my parent/guardian rents	44 (40.7%)	17 (36.0%)	27 (43.6%)		
In an apartment that my parent/guardian rents	8 (7.4%)	5 (10.9%)	3 (4.8%)		
In a shelter	2 (1.9%)	0 (0.0%)	2 (3.2%)		
Other	4 (3.7%)	3 (6.5%)	1 (1.6%)		
Proportion of Condom Use for Vaginal Sex [Median (Q1, Q3)] (n=66)	1.0 (0.3, 1)	0.92 (0.5, 1)	1.0 (0.28, 1)	0.8538	0.001
Number of Sexual Partners in the Past 3 Months [Median (Q1, Q3)] (n=97)	1.0 (1, 3)	2.0 (1, 3)	1.0 (1, 2)	0.4677	0.01

Note: SD=standard deviation; Q1=lower quartile; Q3=upper quartile.

<sup>&</sup>lt;sup>1</sup>P-values based on two-sample t-tests or Wilcoxon rank-sum tests for continuous variables, as appropriate; Fisher's exact tests was used for categorical variables with cells containing less than 5 participants, and chi-square tests for all other categorical variables.

<sup>&</sup>lt;sup>2</sup>Effect sizes based on Cohen's d for age (small: 0.20, medium: 0.50, large: 0.80) or  $\eta^2$  (eta-squared) for proportion of condom use and number of sexual partners (small: 0.01, medium: 0.06, large: >0.14); Cramer's V(weak: 0.10-0.30, medium: 0.40-0.50, large: >0.50) was used for all categorical variables (intervention condition, gender, living status).

Brawner et al. Page 18

Table 4.

Descriptive Statistics for Primary and Secondary Outcomes at Each Time Point by Intervention Condition.

	HIV I	HIV Intervention (N=52)	Gene	General Health (N=56)		
	u	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
Proportion of Cor	ndom U	Proportion of Condom Use for Vaginal Sex in the Past 3 Months	the Past	3 Months		
Baseline	30	0.64 (0.42) 0.92 (0.20, 1)	36	0.67 (0.39) 1 (0.42, 1)	0.7689	0.001
3 Months	21	0.77 (0.37) 1 (0.50, 1)	20	0.64 (0.38) 0.67 (0.33, 1)	0.2138	0.04
6 Months	6	0.58 (0.43) 0.60 (0.26, 1)	12	0.72 (0.35) 0.90 (0.45, 1)	0.4926	0.02
12 Months	S	0.73 (0.44) 1 (0.66, 1)	6	0.91 (0.19) 1 (1, 1)	0.3407	0.04
Number of Sexua	l Partne	Number of Sexual Partners in the Past 3 Months	2			
Baseline	46	2.00 (2.49) 1 (1, 2)	51	2.88 (3.27) 2 (1, 3)	0.0381	0.04
3 Months	34	1.79 (3.00) 1 (1, 1)	24	4.17 (10.39) 1 (1, 3)	0.0561	0.06
6 Months	13	1.00 (0.71) 1 (1, 1)	15	1.67 (1.40) 1 (1, 2)	0.2392	0.05
12 Months	11	1.36 (0.92) 1 (1, 2)	11	1.91 (1.22) 2 (1, 2)	0.3912	0.04
Sex with More th	an One	Sex with More than One Person in the Same Day	ay			
Baseline	52	Yes 25% No 75%	54	Yes 29.6% No 70.4%	0.6657	0.05
3 Months	38	Yes 16% No 84%	31	Yes 26% No 74%	0.3733	0.12
6 Months	17	Yes 6% No 94%%	18	Yes 33.3% No 66.7%	0.0877	0.34
12 Months	111	Yes 27.3% No 72.7%%	12	Yes 33.3% No 66.7%	>0.999	0.07
Sex with More th	an One	Sex with More than One Person in the Same Month	lonth			
Baseline	52	Yes 34.6% No 65.4%	54	Yes 57.4% No 42.6%	0.0209	0.23
3 Months	38	Yes 39.5% No 60.5%	31	Yes 54.5% No 45.2%	0.2324	0.15

	u	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value <sup>I</sup>	Effect Size <sup>2</sup>
6 Months	17	Yes 47.1% No 52.9%	18	Yes 50% No 50%	>0.9999	0.03
12 Months	Ξ	Yes 36.4% No 63.6%	12	Yes 66.7% No 33.3%	0.2203	0.30
Sex While Alread	ly in a	Sex While Already in a Sexual Relationship with Someone Else	ith Son	neone Else		
Baseline	51	Yes 27.5% No 72.5%	54	Yes 42.6% No 57.4%	0.1521	0.16
3 Months	38	Yes 18.4% No 81.6%	31	Yes 38.7% No 61.3%	0.1028	0.23
6 Months	17	Yes 29.4% No 70.6%	18	Yes 38.9% No 61.1%	0.7247	0.10
12 Months	Ξ	Yes 27.3% No 72.7%	12	Yes 41.7% No 58.3%	0.6668	0.15
Alcohol Use in the Past 30 Days	e Past	30 Days				
Baseline	27	1.26 (0.45) 1.00 (1, 2)	26	2.19 (1.81)	0.0104	0.13
3 Months	13	1.15 (0.38) 1.0 (1, 1)	12	1.50 (0.90) 1.0 (1, 2)	0.3056	0.05
6 Months	9	1.50 (0.55) 1.5 (1, 2)	6	1.44 (0.53) 1.0 (1, 2)	>.9999	0.001
12 Months	5	1.40 (0.55) 1.0 (1, 2)	7	1.57 (0.53) 2.0 (1, 2)	>.9999	0.02
Marijuana Use in the Past 30 Days	the Pas	st 30 Days				
Baseline	29	3.31 (2.73) 2 (1, 6)	29	4.31 (3.11) 3 (2, 6)	0.1545	0.04
3 Months	41	4.29 (3.07) 3 (2, 7)	17	3.65 (3.08) 3 (1, 5)	0.5966	0.01
6 Months	∞	2.38 (2.0) 2 (1, 2.5)	=	4.45 (2.91) 4 (2, 7)	0.0824	0.16
12 Months	7	3 (2.65) 2 (1, 5)	9	6.17 (3.37) 5.5 (4, 10)	0.0822	0.23
Condom Use Prevention Beliefs	vention	Beliefs				
Baseline	51	4.08 (1.12) 4.33 (3.67, 5)	99	4.30 (0.79) 4.33 (4, 5)	0.4540	0.01
Immediate Post	47	4.26 (0.86)	48	4.17 (0.93)	0.7109	0.001

	HIV	HIV Intervention (N=52)	Gen	General Health (N=56)		
•	u	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
3 Months	38	4.30 (0.74) 4.33 (4, 5)	33	4.26 (0.74) 4.33 (3.67, 5)	0.7911	0.001
6 Months	17	4.45 (0.56) 4.67 (4, 5)	19	4.23 (0.59) 4 (4, 5)	0.2940	0.03
12 Months	==	4.55 (0.58) 5 (4, 5)	12	4.28 (0.75) 4.50 (3.5, 5)	0.3081	0.04
Condom Use Attitude	tude					
Baseline	50	4.24 (0.72) 4.50 (3.67, 4.67)	99	4.11 (0.65) 4.33 (3.67, 4.67)	0.1939	0.02
Immediate Post	4	4.22 (0.81) 4.33 (4.0, 4.67)	46	3.91 (0.83) 4.0 (3, 4.67)	0.0459	0.04
3 Months	38	4.25 (0.73) 4.33 (3.67, 5)	32	3.95 (0.78) 4 (3.33, 4.5)	0.0846	0.04
6 Months	17	4.08 (0.99) 4.33 (3.67, 5)	19	3.95 (0.87) 4 (3, 5)	0.5434	0.01
12 Months	Ξ	4.03 (0.99) 4.33 (3, 5)	10	4.20 (0.80) 4.33 (3.3, 5)	0.7544	0.005
Condom Use Availability	ilability					
Baseline	51	4.17 (0.61) 4.0 (3.75, 4.75)	55	4.14 (0.54) 4 (3.75, 4.5)	0.6917	0.001
Immediate Post	46	4.20 (0.71) 4.25 (4.0, 4.75)	46	3.90 (0.60) 4.0 (3.5, 4)	0.0096	0.07
3 Months	37	4.19 (0.52) 4.0 (4, 4.5)	31	3.98 (0.65) 4 (3.5, 4.5)	0.0857	0.04
6 Months	17	4.35 (0.55) 4.25 (4, 5)	18	4.21 (0.47) 4 (4, 4.5)	0.3050	0.03
12 Months	Ξ	4.41 (0.59) 4.75 (4, 4.75)	10	4.08 (0.50) 4 (4, 4.25)	0.0903	0.13
Condom Use Hedonistic Beliefs	onistic	Beliefs				
Baseline	49	2.59 (0.31) 2.67 (2.33, 2.83)	53	2.61 (0.35) 2.67 (2.5, 2.83)	0.6089	0.003
Immediate Post	4	2.74 (0.31) 2.83 (2.5, 3)	45	2.72 (0.34) 2.67 (2.5, 3)	0.9817	0.0
3 Months	35	2.68 (0.36) 2.67 (2.5, 3)	31	2.68 (0.32) 2.67 (2.5, 3)	0.8882	0.0
6 Months	17	2.65 (0.37) 2.83 (2.33, 2.83)	19	2.69 (0.34) 2.83 (2.33, 3)	0.7046	0.004

	u	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value <sup>I</sup>	Effect Size <sup>2</sup>
12 Months	11	2.64 (0.43) 2.67 (2.33, 3)	6	2.85 (0.21) 2.83 (2.67, 3)	0.3134	0.05
Condom Use Impulsivity	ulsivity					
Baseline	50	2.15 (0.99) 2 (1.33, 2.67)	54	2.12 (0.98) 2.0 (1.33, 2.67)	0.8199	0.0
Immediate Post	45	1.93 (0.74) 2 (1.33, 2)	46	2.21 (0.90) 2.0 (1.67, 3)	0.1133	0.03
3 Months	38	1.86 (0.74) 2 (1, 2.33)	32	2.30 (0.99) 2.33 (1.67, 3)	0.0420	90.0
6 Months	17	1.88 (0.81) 2 (1, 2.67)	19	2.16 (1.01) 2.0 (1, 3)	0.5350	0.01
12 Months	11	1.85 (0.91) 1.67 (1, 3)	10	1.77 (0.74) 2.0 (1, 2)	0.8878	0.001
Condom Use Negotiation Beliefs	otiation	Beliefs				
Baseline	84	4.24 (0.70) 4.2 (4, 4.8)	55	4.28 (0.63) 4.40 (4, 5)	0.8192	0.001
Immediate Post	4	4.22 (0.66) 4.20 (4, 4.8)	45	4.12 (0.85) 4.20 (3.8, 5)	0.8370	0.0
3 Months	36	4.41 (0.69) 4.70 (4, 5)	32	4.04 (0.67) 4 (3.6, 4.8)	0.0124	0.09
6 Months	17	4.45 (0.58) 4.60 (4, 5)	18	4.18 (0.71) 4 (3.8, 5)	0.2911	0.03
12 Months	11	4.55 (0.54) 4.80 (4, 5)	10	4.22 (0.74) 4 (3.8, 5)	0.3714	0.04
Condom Use Self-efficacy	f-efficac	, A				
Baseline	47	4.14 (0.61) 4 (3.83, 4.67)	51	4.15 (0.46) 4.17 (3.83, 4.5)	0.9347	0.0
Immediate Post	4	4.16 (0.59) 4.17 (3.92, 4.54)	43	4.0 (0.65) 4 (3.67, 4.58)	0.2302	0.02
3 Months	37	4.26 (0.56) 4.25 (4, 4.67)	31	3.95 (0.57) 3.83 (3.5, 4.5)	0.0106	0.10
6 Months	17	4.33 (0.51) 4.42 (4, 4.75)	18	4.12 (0.64) 4.04 (3.83, 4.67)	0.3536	0.03
12 Months	11	4.40 (0.55) 4.33 (3.83, 4.92)	10	4.15 (0.61) 4.0 (3.75, 4.67)	0.4354	0.03
Condom Use Subjective Norm	iective 1	Vorm				

%         n         Mean (SD) or % Acading (IQR)         P-value I           56         4.28 (0.69)         0.9507           47         4.12 (0.92)         0.4099           47         4.12 (0.92)         0.4099           46 (3.5, 5)         0.0202           19         4.16 (0.82)         0.3730           11         4.36 (0.90)         0.7770           53         4.08 (0.63)         0.6037           45         3.88 (0.95)         0.6012           45         4.35, 4.5         0.6012           18         4.14 (0.76)         0.7801           4 (3.5, 4.5)         0.6818           10         4.10 (0.88)         0.6818           10         4.10 (0.88)         0.6818           10         4.10 (0.88)         0.6818           12         0.79 (0.23)         0.5715           13         0.75 (0.32)         0.3368           14         0.75 (0.32)         0.1996           15         0.8 (0.6, 1.0)         0.1996           16         1.99 (0.52)         0.1996		HIIV	HIV Intervention (N=52)	Gen	General Health (N=56)		
4.24 (0.78) 56 4.28 (0.69) 0.9507 4.25 (0.95) 4.5 (4.5) 0.4099 4.5 (4.5) 32 4.08 (0.77) 0.0202 4.5 (4.5) 32 4.08 (0.77) 0.0202 4.5 (4.5) 19 4.12 (0.92) 0.4099 4.5 (4.5) 19 4.16 (0.82) 0.3730 4.5 (4.5) 11 4.36 (0.90) 0.7770 5.32 (0.78) 11 5.3.5 (0.90) 0.7770 4.22 (0.78) 32 4.08 (0.63) 4.4 (4.5) 4.22 (0.80) 32 4.08 (0.63) 4.4 (4.5) 4.22 (0.80) 32 4.35 (4.5) 0.6037 4.24 (0.3.75, 4.5) 4.24 (0.71) 18 4.14 (0.76) 0.7801 4.4 (4.5) 4.24 (0.71) 18 4.14 (0.78) 0.6012 4.4 (4.5) 4.24 (0.71) 18 4.14 (0.78) 0.6012 4.3 (0.67 (0.28) 55 0.80 (0.21) 0.7513 0.80 (0.6, 0.8) 55 0.80 (0.6, 1.0) 0.7513 0.80 (0.6, 0.8) 12 0.75 (0.23) 0.80 (0.8, 1.0) 12 0.75 (0.23) 1.91 (0.6, 1.0) 0.80 (0.8, 1.0) 12 0.80 (0.8, 1.0) 1.99 (0.23) 2.1.75, 2.5) 0.3937 2.1.75, 2.5) 0.3937		п	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
4.25 (0.95) 4.5 (4, 5) 4.5 (4, 5) 4.5 (4, 5) 4.5 (4, 5) 4.5 (4, 5) 4.10 (0.82) 4.10 (0.82) 4.10 (0.82) 4.10 (0.82) 4.10 (0.83) 4.10 (0.83) 4.10 (0.84) 4.10 (0.84) 4.2 (0.75) 4.2 (0.75) 4.2 (0.75) 4.2 (0.75) 4.3 (0.75) 4.3 (0.75) 4.4 (0.75) 4.	Baseline	51	4.24 (0.78) 4 (4, 5)	56	4.28 (0.69) 4.25 (4, 5)	0.9507	0.0
4.5 (0.62) 32 4.08 (0.77) 0.0202 4.15 (4, 5) 19 4.16 (0.82) 4.35, 5) 4.41 (0.59) 19 4.16 (0.82) 0.3730 4.32 (0.78) 11 4.36 (0.90) 0.7770 5.3.43 (0.90) 0.7770 5.3.43 (0.90) 0.7770 5.3.43 (0.90) 0.7770 5.3.44 (0.90) 0.7770 5.3.8 (0.95) 0.6003 5.3.44 (0.90) 0.7770 5.3.8 (0.95) 0.6003 5.3.2 (0.72) 0.0612 5.4.5 (0.90) 0.7801 5.4.5 (0.90) 0.7801 5.4.5 (0.90) 0.7801 5.4.5 (0.90) 0.7801 5.4.5 (0.90) 0.7801 5.4.5 (0.90) 0.7801 5.4.5 (0.90) 0.7801 5.4.5 (0.90) 0.7801 5.4.5 (0.90) 0.7801 5.5 (0.90) 0.7801 5.5 (0.90) 0.79 (0.23) 0.80 (0.6, 0.8) 0.80 (0.6, 0.8) 0.80 (0.6, 0.8) 0.80 (0.6, 0.8) 0.80 (0.6, 0.8) 0.80 (0.6, 0.8) 0.80 (0.6, 0.8) 0.80 (0.8, 0.9) 0.8	Immediate Post	4	4.25 (0.95) 4.5 (4, 5)	47	4.12 (0.92) 4.5 (3, 5)	0.4099	0.01
441 (0.59)	3 Months	38	4.5 (0.62) 4.75 (4, 5)	32	4.08 (0.77) 4 (3.5, 5)	0.0202	0.08
4.32 (0.78)     11     4.36 (0.90)     0.7770       4.5 (4, 5)     11     4.36 (0.90)     0.7770       4.5 (4, 5)     2.9 (0.80)     4.08 (0.63)     0.6003       4 (3.5, 4.5)     4.08 (0.63)     0.6003       4.02 (0.67)     45     3.88 (0.95)     0.6037       4.02 (0.67)     45     4.35, 4.5)     0.6012       4.22 (0.80)     32     3.92 (0.72)     0.6012       4.24 (0.71)     18     4.14 (0.76)     0.7801       4.24 (0.71)     18     4.14 (0.76)     0.7801       4.27 (0.75)     10     4.10 (0.88)     0.6818       4.3.5, 5)     10     4.35, 5)     0.6818       6.67 (0.28)     55     0.69 (0.27)     0.7513       0.80 (0.6, 0.8)     55     0.8 (0.6, 1.0)     0.79 (0.23)       0.84 (0.25)     12     0.75 (0.32)     0.3368       1 (0.6, 1.0)     12     0.75 (0.32)     0.1996       2 (1.75, 2.5)     2 (1.75, 2.5)     0.3937       2 (1.75, 2.5)     2 (1.75, 2.5)     0.3937	6 Months	17	4.41 (0.59) 4.5 (4, 5)	19	4.16 (0.82) 4 (3.5, 5)	0.3730	0.02
Skills       3.99 (0.80)     5.3     4.08 (0.63)     0.6003       4 (3.5, 4.5)     5.3     4 (4, 4.5)     0.6003       4 (3.5, 4.5)     4.3 (3.5, 4.5)     0.6037       4 (3.5, 4.5)     3.2 (0.72)     0.0612       4 (4, 5)     3.92 (0.72)     0.0612       4 (4, 5)     4 (3.5, 4.5)     0.0612       4 (4, 5)     4 (4, 5)     0.7801       4 (4, 5)     4 (4, 5)     0.7801       4 (3.5, 5)     10     4 (3.5)     0.6818       0.67 (0.28)     5.5     0.69 (0.27)     0.7513       0.80 (0.6, 0.8)     5.5     0.89 (0.6, 1.0)     0.7513       0.84 (0.20)     18     0.79 (0.23)     0.5715       0.84 (0.20)     18     0.75 (0.32)     0.1996       2.03 (0.53)     56     1.91 (0.51)     0.1996       2.09 (0.51)     2 (1.75, 2.5)     0.3937       2 (1.75, 2.5)     2 (1.75, 2.5)     0.3937	12 Months	11	4.32 (0.78) 4.5 (4, 5)	11	4.36 (0.90) 5 (3, 5)	0.7770	0.004
3.99 (0.80) 4 (3.5,4.5) 4 (3.5,4.5) 4 (3.5,4.5) 4 (4,4.5) 4 (0.3.75,4.5) 4 (0.3.75,4.5) 4 (3.5,4.5) 4 (3.5,4.5) 4 (3.5,4.5) 4 (3.5,4.5) 4 (3.5,4.5) 4 (3.5,4.5) 4 (3.5,4.5) 4 (3.5,4.5) 6 (3.24 (0.71) 6 (3.24 (0.71) 6 (3.24 (0.71) 6 (3.24 (0.71) 6 (3.24 (0.71) 6 (3.24 (0.71) 6 (3.24 (0.72) 6	Condom Use Tec	hnical 3	Skills				
4.02 (0.67)       45       3.88 (0.95)       0.6037         4.0 (3.75, 4.5)       4 (3.5, 4.5)       0.6012         4.22 (0.80)       32       3.92 (0.72)       0.0612         4.24 (0.71)       18       4.14 (0.76)       0.7801         4.24 (0.71)       18       4.14 (0.76)       0.7801         4.27 (0.75)       10       4.10 (0.88)       0.6818         4.3.5, 5)       10       4.06 (0.27)       0.7513         0.67 (0.28)       55       0.69 (0.27)       0.7513         -       -       -       -       -         -       -       -       -       -         0.84 (0.20)       18       0.75 (0.23)       0.5715         0.84 (0.25)       12       0.75 (0.32)       0.3368         1 (0.6, 1.0)       12       0.8 (0.8, 1.0)       0.8 (0.8, 1.0)         2 (1.75, 2.5)       56       1.91 (0.51)       0.1996         2 (1.75, 2.5)       2 (1.75, 2.5)       0.3937	Baseline	47	3.99 (0.80) 4 (3.5, 4.5)	53	4.08 (0.63) 4 (4, 4.5)	0.6003	0.003
4.22 (0.80)       32       3.92 (0.72)       0.0612         4 (4,5)       4 (3.5, 4.5)       0.0612         4.24 (0.71)       18       4.14 (0.76)       0.7801         4.27 (0.75)       10       4.10 (0.88)       0.6818         4.3.5, 5)       10       4.06 (0.88)       0.6818         0.67 (0.28)       55       0.69 (0.27)       0.7513         0.80 (0.6, 0.8)       55       0.8 (0.6, 1.0)       0.7513         0.84 (0.20)       18       0.79 (0.23)       0.5715         0.84 (0.25)       12       0.75 (0.32)       0.3368         1 (0.6, 1.0)       12       0.8 (0.8, 1.0)       0.8 (0.8, 1.0)       0.1996         2.03 (0.53)       56       1.91 (0.51)       0.1996         2 (1.75, 2.5)       2 (1.75, 2.5)       0.3937	Immediate Post	4	4.02 (0.67) 4.0 (3.75, 4.5)	45	3.88 (0.95) 4 (3.5, 4.5)	0.6037	0.003
4.24 (0.71)     18     4.14 (0.76)     0.7801       4 (4, 5)     4 (4, 5)     0.7801       4.27 (0.75)     10     4.10 (0.88)     0.6818       4 (3.5, 5)     10     4.10 (0.88)     0.6818       0.67 (0.28)     55     0.69 (0.27)     0.7513       0.80 (0.6, 0.8)     5     0.8 (0.6, 1.0)     0.7513       0.84 (0.20)     18     0.79 (0.23)     0.5715       0.84 (0.25)     12     0.75 (0.32)     0.3368       1 (0.6, 1.0)     12     0.75 (0.32)     0.3368       2.03 (0.53)     56     1.91 (0.51)     0.1996       2.09 (0.51)     49     1.99 (0.52)     0.3937       2 (1.75, 2.5)     2 (1.75, 2.5)     0.3937	3 Months	38	4.22 (0.80) 4 (4, 5)	32	3.92 (0.72) 4 (3.5, 4.5)	0.0612	0.05
4.27 (0.75)     10     4.10 (0.88)     0.6818       4 (3.5, 5)     10     4 (3, 5)     0.6818       0.67 (0.28)     55     0.69 (0.27)     0.7513       0.80 (0.6, 0.8)     55     0.80 (0.6, 1.0)     0.7513       -     -     -     -       -     -     -     -       -     -     -     -       -     -     -     -       0.84 (0.20)     18     0.79 (0.23)     0.5715       0.8 (0.8, 1.0)     18     0.8 (0.6, 1.0)     0.3368       1 (0.6, 1.0)     12     0.8 (0.8, 1.0)     0.3368       2 (0.75, 2.5)     56     1.91 (0.51)     0.1996       2 (0.75, 2.5)     2 (0.75, 2.5)     0.3937       2 (1.75, 2.5)     2 (1.75, 2.5)     0.3937	6 Months	17	4.24 (0.71) 4 (4, 5)	18	4.14 (0.76) 4 (4, 5)	0.7801	0.002
0.67 (0.28) 55 0.69 (0.27) 0.7513 0.80 (0.6, 0.8) 55 0.8 (0.6, 1.0) 0.7513 	12 Months	11	4.27 (0.75) 4 (3.5, 5)	10	4.10 (0.88) 4 (3, 5)	0.6818	0.01
0.67 (0.28) 55 0.69 (0.27) 0.7513 0.80 (0.6, 0.8) 55 0.8 (0.6, 1.0) 0.7513 	Condom Knowle	lge					
0.84 (0.20)	Baseline	50	0.67 (0.28) 0.80 (0.6, 0.8)	55	0.69 (0.27) 0.8 (0.6, 1.0)	0.7513	0.001
0.84 (0.20)	Immediate Post	1	1	•	1	•	•
0.84 (0.20) 0.8 (0.6.1.0) 0.5715 0.8 (0.8, 1.0) 0.8 (0.6, 1.0) 0.5715 0.84 (0.25) 12 0.75 (0.32) 0.3368 1 (0.6, 1.0) 12 0.8 (0.8, 1.0) 0.3368 2.03 (0.53) 56 1.91 (0.51) 0.1996 2.09 (0.51) 49 1.99 (0.52) 0.3937 2 (1.75, 2.5) 0.3937	3 Months		1	•	1	1	•
0.84 (0.25) 12 0.75 (0.32) 0.3368 1 (0.6, 1.0) 0.3 (0.8, 1.0) 0.3	6 Months	17	0.84 (0.20) 0.8 (0.8, 1.0)	18	0.79 (0.23) 0.8 (0.6, 1.0)	0.5715	0.01
2.03 (0.53) 56 1.91 (0.51) 0.1996 2 (1.75, 2.5) 56 1.88 (1.50, 2.25) 0.1996 2.09 (0.51) 49 1.99 (0.52) 0.3937 2 (1.75, 2.5) 0.3937	12 Months	Ξ	0.84 (0.25) 1 (0.6, 1.0)	12	0.75 (0.32) 0.8 (0.8, 1.0)	0.3368	0.04
51 2.03 (0.53) 56 1.91 (0.51) 0.1996 2 (1.75, 2.5) 56 1.88 (1.50, 2.25) 0.1996 45 2.09 (0.51) 49 1.99 (0.52) 0.3937	Anger Inhibition	Scale					
45 2.09 (0.51) 49 1.99 (0.52) 0.3937 2 (1.75, 2.5) 0.3937	Baseline	51	2.03 (0.53) 2 (1.75, 2.5)	99	1.91 (0.51) 1.88 (1.50, 2.25)	0.1996	0.02
	Immediate Post	45	2.09 (0.51) 2 (1.75, 2.5)	49	1.99 (0.52) 2 (1.75, 2.5)	0.3937	0.01

	HIV	HIV Intervention (N=52)	Gen	General Health (N=56)		
-	g	Mean (SD) or % Median (IQR)	=	Mean (SD) or % Median (IQR)	$\text{P-value}^I$	Effect Size
3 Months	38	2.09 (0.55) 2 (1.75, 2.5)	33	1.92 (0.61) 2 (1.5, 2.5)	0.2727	0.02
6 Months	17	2.22 (0.5) 2.25 (2, 2.5)	20	1.95 (0.51) 2 (1.75, 2.13)	0.0917	0.08
12 Months	11	2.0 (0.69) 2 (1.5, 2.5)	12	2.0 (0.37) 2 (1.75, 2.25)	0.9750	0.0
Anger Dysregulation Scale	ion Sca	ıle				
Baseline	51	1.76 (0.62) 1.67 (1.33, 2.33)	99	1.70 (0.51) 1.67 (1.33, 2)	0.7037	0.001
Immediate Post	46	1.81 (0.49) 2.0 (1.33, 2)	49	1.79 (0.41) 1.67 (1.33, 2)	0.8541	0.0
3 Months	37	1.57 (0.47) 1.33 (1.33, 1.67)	33	1.74 (0.45) 1.67 (1.67, 2)	0.0675	0.05
6 Months	17	1.80 (0.60) 1.67 (1.33, 2.33)	20	1.83 (0.50) 2 (1.5, 2)	0.6637	0.01
12 Months	11	2.12 (0.78) 2.0 (1.67, 3.0)	12	1.75 (0.53) 1.67 (1.5, 2)	0.3129	0.04
Anger Coping Scale	ale					
Baseline	51	2.24 (0.52) 2.25 (2, 2.75)	99	2.2 (0.45) 2 (2, 2.5)	0.6476	0.002
Immediate Post	46	2.24 (0.48) 2 (2, 2.5)	49	2.28 (0.47) 2.25 (2, 2.75)	0.6294	0.002
3 Months	38	2.41 (0.48) 2.5 (2, 3)	33	2.29 (0.49) 2.25 (2, 2.75)	0.3009	0.02
6 Months	17	2.47 (0.51) 2.5 (2, 3)	18	2.24 (0.53) 2 (2, 2.75)	0.2204	0.04
12 Months	Ξ	1.89 (0.52) 2 (1.5, 2.25)	12	2.17 (0.43) 2 (1.88, 2.5)	0.2418	90.0
Sadness Inhibition Scale	n Scale					
Baseline	52	2.09 (0.63) 2 (1.5, 2.63)	56	2.07 (0.59) 2.0 (1.75, 2.5)	0.8258	0.0
Immediate Post	4	2.1 (0.62) 2 (1.63, 2.75)	4	2.13 (0.55) 2 (1.75, 2.5)	0.8257	0.001
3 Months	38	2.15 (0.53) 2 (1.75, 2.5)	33	2.06 (0.53) 2 (1.75, 2.5)	0.5756	0.004
6 Months	17	2.13 (0.54) 2 (1.75, 2.5)	19	1.99 (0.54)	0.9871	0.0

	Ē	HIV Intervention (N=52)	Sen	General Health (N=50)		
	п	Mean (SD) or % Median (IQR)	п	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
12 Months	11	2.05 (0.72) 2.25 (1.25, 2.5)	12	2.19 (0.30) 2 (2, 2.5)	0.8505	0.002
Sadness Dysregulation Scale	lation S	cale				
Baseline	51	1.42 (0.47) 1.33 (1, 1.67)	55	1.44 (0.47) 1.33 (1, 1.67)	0.8051	0.001
Immediate Post	4	1.61 (0.56) 1.67 (1, 2)	45	1.71 (0.53) 1.67 (1.33, 2)	0.3416	0.01
3 Months	37	1.51 (0.48) 1.33 (1, 2)	33	1.58 (0.43) 1.67 (1.33, 2)	0.4357	0.01
6 Months	17	1.59 (0.56) 1.67 (1, 2)	19	1.60 (0.55) 1.33 (1, 2)	0.9094	0.0
12 Months	Ξ	2.03 (0.69) 2 (1.33, 2.67)	12	1.58 (0.47) 1.5 (1.17, 2)	0.1184	0.11
Sadness Coping Scale	Scale					
Baseline	51	2.23 (0.50) 2.2 (1.8, 2.6)	53	2.31 (0.48) 2.2 (2, 2.6)	0.3795	0.01
Immediate Post	4	2.27 (0.46) 2.2 (2, 2.6)	45	2.28 (0.49) 2.2 (2, 2.8)	0.7447	0.001
3 Months	37	2.26 (0.46) 2.2 (2, 2.6)	33	2.37 (0.44) 2.4 (2, 2.8)	0.4358	0.01
6 Months	17	2.35 (0.46) 2.4 (2, 2.6)	19	2.17 (0.45) 2.2 (2, 2.6)	0.2478	0.04
12 Months	11	1.95 (0.54) 2 (1.4, 2.2)	12	2.32 (0.39) 2.2 (2, 2.6)	0.0918	0.12
Pro-Black Ethnic Identity Score	Identit	y Score				
Baseline	51	3.40 (0.39) 3.43 (3, 3.71)	54	3.37 (0.43) 3.43 (3, 3.71)	0.7174	0.001
Immediate Post	46	3.54 (0.35) 3.57 (3.29, 3.86)	48	3.50 (0.52) 3.57 (3.21, 3.86)	0.7198	0.001
3 Months	38	3.48 (0.42) 3.57 (3.29, 3.86)	32	3.44 (0.44) 3.43 (3, 3.93)	0.6816	0.002
6 Months	16	3.51 (0.52) 3.64 (3.07, 4)	20	3.49 (0.43) 3.57 (3.07, 3.86)	0.7223	0.004
12 Months	11	3.55 (0.42) 3.57 (3, 3.86)	12	3.46 (0.33) 3.50 (3.14, 3.71)	0.5758	0.01
Anti-White Ethnic Identity Score	c Ident	ity Score				

	HIIV	HIV Intervention (N=52)	Gen	General Health (N=56)		
	п	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
Baseline	51	1.99 (0.49) 2 (1.5, 2.25)	52	1.99 (0.49) 2 (1.75, 2.25)	0.8357	0.0
Immediate Post	45	1.94 (0.55) 2 (1.5, 2.25)	46	1.96 (0.56) 2 (1.75, 2.25)	0.8427	0.0
3 Months	37	1.97 (0.56) 2 (1.5, 2.25)	28	2.04 (0.70) 2.0 (1.5, 2.5)	0.6544	0.003
6 Months	15	1.77 (0.67) 1.75 (1, 2.25)	18	2.14 (0.55) 2.13 (1.75, 2.5)	0.0733	0.10
12 Months	11	1.82 (0.40) 1.75 (1.5, 2)	11	1.98 (0.36) 2 (1.75, 2.25)	0.4186	0.03
Racism Awareness Ethnic Identity Score	ss Ethni	ic Identity Score				
Baseline	49	2.82 (0.45) 2.80 (2.6, 3.2)	52	2.95 (0.50) 3 (2.6, 3.4)	0.2185	0.02
Immediate Post	4	2.87 (0.47) 2.8 (2.6, 3.2)	43	2.94 (0.55) 3 (2.6, 3.4)	0.6016	0.003
3 Months	37	2.97 (0.56) 3 (2.6, 3.2)	32	3.12 (0.59) 3 (2.8, 3.7)	0.3855	0.01
6 Months	16	2.72 (0.49) 2.7 (2.4, 3)	20	3.15 (0.55) 3.2 (2.7, 3.6)	0.0163	0.16
12 Months	Ξ	2.76 (0.67) 2.8 (2.4, 3.4)	12	3.03 (0.67) 2.9 (2.7, 3.8)	0.2363	90.0
Attitudes Toward Women Score	Wome	n Score				
Baseline	48	1.97 (0.34) 2 (1.71, 2.17)	49	2.04 (0.43) 2.08 (1.83, 2.33)	0.2296	0.02
Immediate Post	4	2.93 (0.36) 2.92 (2.67, 3.17)	4	2.92 (0.44) 2.88 (2.54, 3.25)	0.6656	0.002
3 Months	36	1.96 (0.40) 2.08 (1.58, 2.25)	29	2.02 (0.41) 2.0 (1.83, 2.42)	0.6908	0.002
6 Months	15	2.01 (0.54) 2.08 (1.75, 2.58)	16	2.02 (0.45) 2.17 (1.79, 2.33)	0.9367	0.0
12 Months	10	2.03 (0.44) 2 (1.83, 2.25)	12	2.03 (0.44) 2.17 (1.71, 2.38)	0.8427	0.002
HIV/STD Knowledge Scale Score	edge Sc	cale Score				
Baseline	50	0.64 (0.22) 0.71 (0.57, 0.79)	55	0.63 (0.21) 0.71 (0.57, 0.79)	0.7068	0.001
Immediate Post	45	0.64 (0.27) 0.67 (0.50, 0.83)	45	0.48 (0.25) 0.50 (0.33, 0.67)	0.0028	0.10

	HIV	HIV Intervention (N=52) General Health (N=56)	Gene	ral Health (N=56)		
	п	Mean (SD) or % Median (IQR)	п	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
3 Months 36	36	0.73 (0.21) 0.79 (0.64, 0.86)	30	0.57 (0.27) 0.57 (0.36, 0.79)	0.0107	0.10
6 Months	17	0.76 (0.21) 0.79 (0.71, 0.86)	18	0.72 (0.18) 0.71 (0.71, 0.86)	0.4011	0.02
12 Months	11	0.77 (0.19) 0.86 (0.64, 0.93)	12	0.70 (0.24) 0.75 (0.54, 0.86)	0.4736	0.02
Total PHQ-9 Score	re					
Baseline	52	3.17 (2.82) 2 (1, 5)	55	2.67 (3.07) 2 (0, 4)	0.1743	0.02

5) 0.4595 0.02	
13 3(1,5)	tile range
1 (0, 6)	Note: SD=standard deviation; IQR=interquartile range
Ξ	l devi
12 Months	Note: SD=standard

0.002

0.7727

3.23 (4.06) 2 (0, 5)

22

2.94 (3.34) 2 (1, 3)

17

6 Months

0.001

0.7846

2.80 (3.79) 2 (0, 4)

51

2.19 (2.51) 2 (0, 3)

47

Immediate Post

0.01

0.3350

4.24 (5.35) 3 (0, 7)

33

2.82 (3.61) 1 (0, 5)

38

3 Months

2 Effect sizes are based on  $\eta^2$  (eta-squared) for continuous variables (small: 0.01, medium: 0.06, large: >0.14) and Cramer's Vfor categorical variables (small: 0.10-0.29, medium: 0.30-0.50, large: >0.50). I-values are based on non-parametric exact Wilcoxon rank-sum tests for continuous variables and Fisher's exact tests for categorical variables

Table 5.

Descriptive Statistics of Change from Baseline for Primary and Secondary Outcomes by Intervention Condition.

[	HIV	HIV Intervention (N=52)	Gen	General Health (N=56)		
I	g g	Mean (SD) or % Median (IQR)	=	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
Change from Basel	line ir	Change from Baseline in Proportion of Condom Use for Vaginal Sex in the Past 3 Months	n Use f	or Vaginal Sex in the	Past 3 Month	sı
3 Months	16	0.21 (0.39) 0 (0, 0.50)	13	-0.02 (0.53) 0 (-0.33, 0.33)	0.1976	90.0
6 Months	∞	0.01 (0.35) 0 (0, 0.20)	9	0.22 (0.53) 0.07 (0, 0.67)	0.4655	0.04
12 Months	5	0.04 (0.43) 0 (-0.20, 0)	7	0.52 (0.41) 0.50 (0, 1)	0.0833	0.23
Change from Basel	line ir	Change from Baseline in Number of Sexual Partners in the Past 3 Months	rtners i	n the Past 3 Months		
3 Months	32	0.22 (1.60) 0 (-1, 0.50)	23	2.35 (10.76) 0 (-1, 1)	0.6045	0.005
6 Months	13	-0.54 (0.97) -1 (-1, 0)	4	-0.57 (2.77)  0 $(-1, 1)$	0.2375	0.05
12 Months	11	-0.09 (0.94) 0 $(-1, 0)$	6	-0.56 (2.92) 0 (0, 0)	0.7307	0.005
ex with More than	ı One	Sex with More than One Person in the Same Day	ay			
3 Months	38	Yes to Yes 10.5% Yes to No 7.9% No to Yes 5.3% No to No 76.3%	31	Yes to Yes 22.6% Yes to No 16.1% No to Yes 3.2% No to No 58.1%	0.3360	0.23
6 Months	17	Yes to Yes 5.9% Yes to No 11.8% No to Yes 0%	18	Yes to Yes 27.8% Yes to No 0% No to Yes 5.6%	0.0832	0.41
12 Months	=	No to No 82.4% Yes to Yes 18.2% Yes to No 0% No to Yes 9.1% No to No 72.7%	11	No to No 51.4% Yes to Yes 18.2% Yes to No 18.2% No to Yes 9% No to No 54.6%	0.7470	0.32
sex with More than	) One	Sex with More than One Person in the Same Month	onth			
3 Months	38	Yes to Yes 23.7% Yes to No 7.9% No to Yes 15.8% No to No 52.6%	31	Yes to Yes 45.2% Yes to No 12.9% No to Yes 9.7% No to No 32.3%	0.1851	0.27
6 Months	17	Yes to Yes 23.5% Yes to No 11.8%	18	Yes to Yes 44.4% Yes to No 5.6%	0.3784	0.32

	HIV	HIV Intervention (N=52)	Gen	General Health (N=56)		
	=	Mean (SD) or % Median (IQR)	g	Mean (SD) or % Median (IQR)	$^{-}$ P-value	Effect Size <sup>2</sup>
		No to Yes 23.5% No to No 41.2%		No to Yes 5.6% No to No 44.4%		
12 Months	11	Yes to Yes 18.2% Yes to No 18.2% No to Yes 18.2% No to No 45.4%	11	Yes to Yes 45.4% Yes to No 18.2% No to Yes 18.2% No to No 18.2%	0.3971	0.34
Sex While Already in a	dy in a	Sexual Relationship with Someone Else	ith Som	eone Else		
3 Months	37	Yes to Yes 8.1% Yes to No 13.5% No to Yes 10.8% No to No 67.6%	31	Yes to Yes 32.3% Yes to No 9.7% No to Yes 6.5% No to No 51.6%	0.0978	0.31
6 Months	17	Yes to Yes 17.7% Yes to No 11.8% No to Yes 11.8% No to No 58.8%	18	Yes to Yes 33.3% Yes to No 11.1% No to Yes 5.6% No to No 50%	0.8237	0.20
12 Months	11	Yes to Yes 9.1% Yes to No 18.2% No to Yes 18.2% No to No 54.6%	11	Yes to Yes 36.4% Yes to No 9% No to Yes 9% No to No 45.6%	0.5621	0.34
Change from Bas	seline ii	Change from Baseline in Alcohol Use Past 30 Days	Days			
3 Months	10	0.0 (0.47)	∞	-0.38 (0.74) -0.50 (-1, 0)	0.1604	0.10
6 Months	2	0.50 (0.71) 0.5 (0, 1)	9	-1.50 (2.17) -1 (-3, 0)	0.2857	0.18
12 Months	4	-0.25 (0.50) 0.0 (-0.5, 0)	5	-1.60 (2.41) -1 (-3, 0)	0.5000	0.05
Change from Bas	seline ii	Change from Baseline in Marijuana Use in the Past 30 Days	Past 30	) Days		
3 Months	12	0.67 (3.28) 1 (-0.5, 2)	15	-1.53 (4.0) 0 $(-3,0)$	0.1012	0.10
6 Months	7	-1.0 (2.94) -1 (-4, 0)	∞	-0.88 (1.96) -0.5 (-1.5, 0.5)	0.8014	0.004
12 Months	S	-0.4 (4.72) 0.0 (-5, 2)	4	-0.75 (1.71) -0.5 (-2, 0.5)	0.9603	<0.001
Change from Bas	seline ii	Change from Baseline in Condom Use Prevention Beliefs	tion Bel	iefs		
Immediate Post	47	0.20 (1.15)	84	-0.11 (0.84) 0.0 (-0.33, 0.33)	0.3265	0.01
3 Months	38	0.27 (1.23)	33	-0.09 (0.83)	0.6942	0.002

Median (1QR)   Median (1QR)   Median (1QR)   P-vailed   Effect Size Median (1QR)   Median (1QR)   P-vailed   Effect Size Median (1QR)   P-vailed   Effect Size Median (1QR)   P-vailed		HIV	HIV Intervention (N=52)	Gen	General Health (N=56)		
17 $0.43 (1.30)$ 19 $0.02 (0.93)$ $0.4731$ 11 $0.61 (1.39)$ 12 $0.0 (-0.67)$ $0.3616$ 11 $0.61 (1.39)$ 12 $0.0 (0.94)$ $0.3616$ 11 $0.61 (1.39)$ 12 $0.0 (0.94)$ $0.3616$ 43 $-0.09 (0.94)$ 46 $-0.19 (0.74)$ $0.4786$ 43 $-0.09 (0.94)$ 32 $-0.04 (0.81)$ $0.4786$ 38 $-0.05 (0.8)$ 32 $-0.04 (0.81)$ $0.9138$ 17 $-0.29 (1.06)$ 19 $-0.26 (0.56)$ $0.7820$ 18eline in Condom Use Availability $0.00 (0.073)$ 46 $-0.24 (0.69)$ $0.7424$ 45 $-0.02 (0.79)$ 46 $-0.24 (0.69)$ $0.7424$ 56 $0.(-0.25, 0.5)$ 47 $0.02 (0.60)$ $0.7424$ 57 $0.09 (0.80)$ 10 $0.02 (0.25)$ $0.7424$ 58 $0.00 (0.84)$ 11 $0.09 (0.80)$ $0.02 (0.25)$ $0.7424$ 58 $0.00 (0.25, 0.2$		u	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
11 0.61 (1.39) 12 0.0 (0.94) 0.3616  43 0.00, 23 0.33 46 0.19 (0.74) 0.4786  43 0.00, 0.33, 0.33 46 0.00, 0.33, 0.33 0.4786  38 0.00, 0.33 32 0.00, 0.0.57, 0.50  17 0.00, 0.03, 0.33 19 0.00, 0.03, 0.33, 0.03888  18 0.00, 0.33 10 0.00, 0.00, 0.03, 0.03, 0.03888  11 0.00, 0.03, 0.04 0.03 10 0.00, 0.03, 0.03, 0.03888  45 0.00, 0.03, 0.04 0.09 0.04 0.09 0.040  46 0.00, 0.03, 0.03 0.06 0.00, 0.00, 0.03, 0.03, 0.03 0.00, 0.00, 0.00, 0.03, 0.03, 0.00, 0	6 Months	17	0.43 (1.30) 0.0 (-0.33, 1)	19	0.02 (0.93) 0.0 (-1, 0.67)	0.4731	0.01
seline in Condom Use Attitude  43	12 Months	Ξ	0.61 (1.39) 0 (0, 2)	12	0.0 (0.94)	0.3616	0.04
43	Change from Bas	seline i	n Condom Use Attitude	,			
38	Immediate Post	43	-0.09 (0.94) 0 (-0.33, 0.33)	46	-0.19 (0.74) 0 (-0.33, 0.33)	0.4786	0.01
17	3 Months	38	-0.05 (0.8) 0 (0, 0.33)	32	-0.04 (0.81) 0 (-0.5, 0.5)	0.9138	<0.001
11	6 Months	17	-0.29 (1.06) 0 (-0.67, 0.33)	19	-0.26 (0.56) 0 (-0.67, 0)	0.7820	0.002
aseline in Condom Use Availability  45	12 Months	11	-0.39 (1.04) 0 (-1.33, 0.33)	10	-0.13 (0.82) $0 (-0.33, 0)$	0.8858	0.001
45	Change from Bas	seline i	n Condom Use Availab	ility			
36 0.03 (0.66) 30 0.04 (0.90) 0.7424  17 0.09 (0.84) 17 0.06 (0.58) 0.7941  18 0.09 (0.80) 10 0.00 (0.058) 0.7941  19 0.09 (0.80) 10 0.00 (0.071) 0.6966  11 0.09 (0.80) 10 0.00 (0.071) 0.6966  43 0.17 (0.40) 44 0.17 (0.08, 0.33) 0.8408  35 0.04 (0.30) 30 0.09 (0.40) 0.7161  17 0.02 (0.34) 18 0.02 (0.41) 0.7395  18 0.02 (0.41) 0.33) 0.7850  19 0.02 (0.40) 0.00 (0.040) 0.7850  44 0.02 (0.40) 0.30 0.00 (0.00) 0.7853  37 0.02 (0.67, 0.33) 31 0.08 (0.99) 0.2483  37 0.023 (0.91) 31 0.08 (0.99) 0.02483	Immediate Post	45	-0.02 (0.79) 0 (-0.25, 0.5)	46	-0.24 (0.69) 0 (-0.75, 0.25)	0.1581	0.02
17 0.09 (0.84) 17 0.06 (0.58) 0.7941  18 0.09 (0.80) 10 0 (0.071) 0.6966  19 0.09 (0.80) 10 0 (0.071) 0.6966  aseline in Condom Use Hedonistic Beliefs  43 0.17 (0.40) 44 0.17 (0.08, 0.33) 0.8408  35 0.04 (0.30) 30 0.09 (0.40) 0.5161  17 0.02 (0.34) 18 0.02 (0.41) 0.7395  18 0.02 (0.41) 0.33 0 0.04 (0.33) 0.7395  19 0.02 (0.40) 0.00 (0.40) 0.7850  44 0.02 (0.40) 0.00 (0.017, 0.33) 0.7850  44 0.09 (0.00) 0.00 (0.00) 0.00 (0.00)  37 0.02 (0.60) 0.30 0.00 (0.00) 0.00 (0.00)  38 0.02 (0.60) 0.00 (0.00) 0.00 (0.00)  49 0.02 (0.40) 0.00 (0.00) 0.00 (0.00)  40 0.02 (0.60) 0.33 0.33 0 0.2483	3 Months	36	0.03 (0.66) 0 (-0.5, 0.25)	30	-0.04 (0.90) 0 $(-0.5, 0.5)$	0.7424	0.002
11 0.09 (0.80) 10 0 (0.71) 0.6966  aseline in Condom Use Hedonistic Beliefs  43 0.17 (0.40) 44 0.10 (0.38) 0.8408  35 0.04 (0.30) 30 0.09 (0.40) 0.5161  17 0.02 (0.34) 18 0.02 (0.41) 0.7395  18 0.02 (0.41) 0.0395  11 0.02 (0.46) 9 0.04 (0.48) 0.7850  aseline in Condom Use Impulsivity  44 0.023 (0.91) 31 0.08 (0.99)  37 0.023 (0.91) 31 0.08 (0.99) 0.2483	6 Months	17	0.09 (0.84) 0 (-0.25, 0.5)	17	0.06 (0.58) 0 (-0.25, 0.25)	0.7941	0.002
43 0.17 (0.40) 43 0.17 (0.40) 44 0.10 (0.38) 55 0.04 (0.30) 60.04 (0.30) 75 0.02 (0.34) 71 0.02 (0.34) 71 0.02 (0.34) 71 0.02 (0.46) 71 0.02 (0.46) 72 0.04 (0.48) 73 0.04 (0.48) 74 0.017 (0.03) 75 0.04 (0.48) 75 0.04 (0.48) 75 0.04 (0.48) 75 0.04 (0.48) 75 0.04 (0.48) 75 0.05 (0.41) 75 0.05 (0.41) 75 0.05 (0.46) 75 0.05 (0.41) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.48) 75 0.05 (0.67) 75 0.05 (0.67) 75 0.05 (0.68) 75 0.05 (0.68) 75 0.05 (0.69) 75 0.05 (0.68) 75 0.05	12 Months	11	0.09 (0.80) 0.5 (-0.75, 0.75)	10	0 (0.71) 0 (-0.5, 0.25)	0.6966	0.01
43 0.17 (0.40) 44 0.10 (0.38) 55 0.04 (0.33) 60.09 (0.40) 17 0.02 (0.34) 18 0.02 (0.41) 19 0.02 (0.44) 19 0.02 (0.44) 11 0.02 (0.46) 11 0.02 (0.46) 11 0.02 (0.46) 12 0.02 (0.46) 13 0.02 (0.46) 14 0.02 (0.40) 15 0.02 (0.40) 17 0.02 (0.46) 18 0.04 (0.48) 19 0.04 (0.48) 10 0.02 (0.46) 11 0.02 (0.46) 11 0.02 (0.46) 12 0.02 (0.46) 13 0.02 (0.46) 14 0.03 (0.33) 15 0.03 (0.99) 17 0.023 (0.91) 18 0.08 (0.99) 19 0.0408	Change from Bas	seline i	n Condom Use Hedoni	stic Be	liefs		
35 0.04 (0.30) 30 0.09 (0.40) 0.5161  17 0.02 (0.34) 18 0.02 (0.41) 0.7395  18 0.02 (0.44) 9 0.02 (0.43) 0.7395  11 0.02 (0.46) 9 0.04 (0.48) 0.7850  12 0.02 (0.46) 9 0.04 (0.48) 0.7850  13 0.02 (0.67, 0.33) 31 0.08 (0.99) 0.5483  37 0.023 (0.91) 31 0.08 (0.99) 0.2483	Immediate Post	43	0.17 (0.40) 0.17 (-0.17, 0.33)	4	0.10 (0.38) 0.17 (-0.08, 0.33)	0.8408	<0.001
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	3 Months	35	0.04 (0.30) 0 (-0.17, 0.33)	30	0.09 (0.40) 0.17 (-0.17, 0.33)	0.5161	0.01
11 $0.02 (0.46)$ 9 $0.04 (0.48)$ 0.7850 seline in Condom Use Impulsivity 44 $0.0.67, 0.33$ 45 $0.12 (0.92)$ 0.5863 37 $0.0.23 (0.91)$ 31 $0.08 (0.99)$ 0.2483	6 Months	17	0.02 (0.34) 0 (-0.17, 0.33)	18	0.02 (0.41) 0 (-0.17, 0.33)	0.7395	0.003
44	12 Months	Ξ	0.02 (0.46) 0 (-0.17, 0.33)	6	0.04 (0.48) 0 (-0.17, 0)	0.7850	0.004
$44 \qquad \begin{array}{ccccc} -0.19 & (1.0) & 45 & 0.12 & (0.92) & 0.5863 \\ 0 & (-0.67, 0.33) & 45 & 0 & (-0.33, 0.33) & 0.5863 \\ 37 & -0.23 & (0.91) & 31 & 0.08 & (0.99) & 0.2483 \\ 0 & (-0.67, 0.33) & 31 & 0 & (-0.67, 0.67) & 0.2483 \end{array}$	Change from Bas	seline i	n Condom Use Impulsi	vity			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Immediate Post	4	-0.19 (1.0) 0 (-0.67, 0.33)	45	0.12 (0.92) 0 (-0.33, 0.33)	0.5863	0.003
	3 Months	37	-0.23(0.91) $0(-0.67, 0.33)$	31	0.08 (0.99) 0 (-0.67, 0.67)	0.2483	0.02

pr.%         n         Mean (SD) or %         P-value           43         18         0.07 (1.21)         0.5237           83         18         0.07 (1.21)         0.5237           80         0.07 (1.21)         0.5237           80         0.027 (0.98)         >0.9999           0.657         10         -0.27 (0.98)         >0.9999           1.Negotiation Beliefs         0.013 (0.89)         0.6874           2)         45         0.03 (0.04, 0.2)         0.6874           3)         45         0.02 (0.86)         0.1832           4)         10         -0.04 (0.82)         0.3212           4)         10         -0.04 (0.82)         0.3212           4)         10         -0.04 (0.82)         0.3212           5)         41         -0.04 (0.82)         0.1339           5)         41         -0.04 (0.82)         0.2135           6)         10         -0.04 (0.82)         0.2135           7)         10         -0.04 (0.62)         0.2135           8elf-Efficacy         10         -0.04 (0.62)         0.2171           8ibjective Norm         10         -0.08 (-0.33, 0.08)         0.2548		HIV	HIV Intervention (N=52)	Gen	General Health (N=56)		
17		u	Mean (SD) or % Median (IQR)	п	Mean (SD) or % Median (IQR)	P-value <sup>I</sup>	Effect Size <sup>2</sup>
seline in Con idom Use Negotiation Beliefs  42	6 Months	17	-0.29 (1.24) $0 (-1.0, 0.33)$	18	0.07 (1.21) 0 (-0.67, 1.0)	0.5237	0.01
42	12 Months	11	-0.27 (1.08) -0.33 (-0.67, 0.67)	10	-0.27 (0.98) 0 (-0.67, 0)	>0.9999	<0.001
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Change from Bas	eline ii	n Con idom Use Negot	iation ]	Beliefs		
34 0.16 (0.60) 32 0.11 (0.87) 0.02 (0.04) 17 0.00 (0.04) 18 0.02 (0.86) 0.00 (0.04) 18 0.02 (0.86) 0.00 (0.04, 0) 0.00 (0.04, 0) 0.00 (0.04, 0) 0.00 (0.04, 0) 0.00 (0.04, 0) 0.00 (0.04, 0) 0.00 (0.04, 0) 0.00 (0.04, 0) 0.00 (0.04, 0) 0.00 (0.05, 0) 0.00 (0.03, 0.33) 0.01 0.013 (0.01) 0.13 (0.01) 0.13 (0.01) 0.13 (0.01) 0.13 (0.01) 0.13 (0.01) 0.13 (0.01) 0.13 (0.01) 0.13 (0.01) 0.13 (0.02) 0.00 (0.05) 0.00 (0.	Immediate Post	42	-0.03 (0.83) 0 (-0.2, 0.2)	45	-0.13 (0.89) 0 (-0.4, 0.2)	0.6874	0.002
17 $0.(0.73)$ 18 $0.02.(0.86)$ $0.(0.04,0)$ $0.(0.04,0)$ $0.(-0.4,0)$ $0.(-0.4,0)$ $0.(-0.2,0.4)$ $0.(-0.6,0)$ $0.(-0.2,0.4)$ $0.(-0.6,0)$ $0.(-0.2,0.4)$ $0.(-0.6,0)$ $0.(-0.2,0.4)$ $0.(-0.6,0)$ $0.(-0.3,0.3)$ $0.33$ $0.12 (0.53)$ $0.31$ $0.12 (0.53)$ $0.13 (0.71)$ $0.31 (0.01)$ $0.13 (0.71)$ $0.31 (0.02,0.2)$ $0.08 (-0.08,0.42)$ $0.08 (-0.08,0.42)$ $0.08 (-0.03,0.21)$ $0.13 (0.71)$ $0.11 (0.43)$ $0.10$ $0.11 (0.43)$ $0.10$ $0.11 (0.43)$ $0.10$ $0.11 (0.43)$ $0.11 (0.43)$ $0.11 (0.43)$ $0.11 (0.43)$ $0.02 (0.70)$ $0.02 (0.70)$ $0.02 (0.70)$ $0.03 (0.90)$ $0.05 (0.05)$ $0.05 (0.55)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$ $0.05 (0.05)$	3 Months	34	0.16 (0.60) 0.20 (0, 0.4)	32	-0.11 (0.87) $0 (-0.7, 0.3)$	0.0585	0.05
11 0 0 (0.46) 10 -0.04 (0.82)    12 0 (-0.2, 0.4) 10 -0.04 (0.82)    13 -0.01 (0.75) 41 -0.08 (-0.42, 0.17)    14 0 (-0.33, 0.33) 41 -0.08 (-0.42, 0.17)    15 0.12 (0.55) 29 -0.01 (0.71)    16 0.02 (-0.03, 0.23)    17 0.13 (0.71)    18 0.11 (0.43)    19 0.12 (0.53)    10 0.11 (0.43)    11 0.25 (-0.33, 0.5)    12 0.03 (0.90)    13 0 0.00 (0.90)    14 0.01 (0.90)    15 0.18 (1.06)    16 0.14 (1.38)    17 0.18 (1.06)    18 0.01 (0.3)    19 0.14 (1.38)    10 0.18 (1.06)    11 0.18 (1.06)    12 0.14 (0.97)    13 0.02 (0.03)    14 0.00 (1.03)    15 0.02 (0.50)    16 0.04 (0.50)    17 0.18 (1.06)    18 0.01 (0.30)    19 0.14 (1.38)    10 0.18 (1.06)    11 0.18 (1.06)    12 0.14 (0.50)    13 0.02 (0.50)    14 0.00 (0.50)    15 0.00 (0.50)    16 0.05 (0.51)    17 0.009 (0.89)    18 0.00 (0.05)    19 0.01 (0.50)    10 0.01 (0.50)     10 0.01 (0.50)    10 0	6 Months	17	0 (0.73) 0 (0, 0.4)	18	0.02 (0.86) 0 (-0.4, 0)	0.1832	0.05
41	12 Months	Ξ	0 (0.46) 0 (-0.2, 0.4)	10	-0.04 (0.82) 0 (-0.6, 0)	0.3212	0.05
41	Change from Bas	eline ii	n Condom Use Self-Eff	ficacy			
34 $0.08 (-0.55)$ $29 -0.11 (0.71)$ $0.08 (-0.08, 0.42)$ $29 -0.08 (-0.5, 0.33)$ $0.13 (0.71)$ $0.31 (-0.25, 0.5)$ $16 -0.04 (0.62)$ $0.13 (0.71)$ $0.11 (0.43)$ $16 -0.12 (-0.33, 0.21)$ $11 0.25 (-0.33, 0.5)$ $10 0.02 (0.70)$ $0.02 (0.70)$ $0.03 (0.90)$ $47 0.06 (-0.33, 0.08)$ $0.03 (0.90)$ $47 0.05 (0.95)$ $0.00 (0.89)$ $0.00 (0.05)$ $0.00 (0.89)$ $0.00 (0.09)$ $0.015 (0.99)$ $0.015 (0.99)$ $0.015 (0.90)$ $0.015 (0.90)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.05)$ $0.018 (1.06)$ $0.018 (1.05)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.018 (1.06)$ $0.009 (0.89)$ $0.009 (0.89)$	Immediate Post	41	-0.01 (0.75) 0 (-0.33, 0.33)	41	-0.14 (0.66) -0.08 (-0.42, 0.17)	0.4806	0.01
17 0.13 (0.71) 16 -0.04 (0.62) 17 (0.33 (-0.25, 0.5) 16 -0.12 (-0.33, 0.21) 18 (-0.12 (-0.33, 0.21) 19 (0.02 (0.70) 11 (0.43) 0.03 (0.93) 10 (0.02 (0.70) 19 (0.0, 0.5) 0.03 (0.90) 19 (0.0, 0.5) 17 (0.0, 0.5) 19 (0.0, 0.5) 17 (0.0, 0.0) 19 (0.0, 0.5) 18 (0.0, 0.0) 19 (0.0, 0.5) 11 (0.18 (1.06) 11 (0.18 (1.06) 11 (0.14 (1.38) 0 (-1, 1.5) 11 (0.14 (1.38) 0 (-1, 1.5) 11 (0.5 (-1, 1.5) 0 (-0.5, 0.5) 11 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) 19 (0.00 (0.03) (0.00 (0.03) 19 (0.00 (0.03) (0.00 (0.03	3 Months	34	0.12 (0.55) 0.08 (-0.08, 0.42)	29	$\begin{array}{c} -0.11 \ (0.71) \\ -0.08 \ (-0.5, 0.33) \end{array}$	0.1339	0.04
11 0.11 (0.43) 10 0.02 (0.70)  12 0.25 (-0.33, 0.5) 10 0.02 (0.70)  13 0.03 (0.90) 47 0.0.5 (0.95)  14 0.015 (0.90) 32 0.0.9 (0.89)  17 0.15 (0.90) 19 0.0.18 (0.97)  18 0.15 (0.90) 19 0.0.18 (0.97)  19 0.18 (1.06) 11 0.14 (1.38)  10 0.0 (1.03) 44 0.0.5 (0.5)  11 0.00 (1.03) 44 0.0.5 (0.5)  12 0.2 (0.81) 32 0.09 (0.89)  13 0.2 (0.81) 32 0.09 (0.89)	6 Months	17	0.13 (0.71) $0.33 (-0.25, 0.5)$	16	-0.04 (0.62) -0.12 (-0.33, 0.21)	0.2135	0.05
43 0.03 (0.90) 47 0.15 (0.95) (0.0.5, 0.5) (0.0.03 (0.90) 47 0.0.05, 0.5) (0.0.05, 0.5) (0.0.05, 0.5) (0.0.00) 38 0.20 (0.90) 32 0.00 (0.89) (0.0.0) 17 0.15 (0.90) 19 0.0.18 (0.97) (0.0.0) 11 0.18 (1.06) 11 0.14 (1.38) (0.1.1, 1.5) (0.1.1,	12 Months	11	0.11 (0.43) 0.25 (-0.33, 0.5)	10	0.02 (0.70) -0.08 (-0.33, 0.08)	0.2171	0.07
43 0.03 (0.95) 47 -0.15 (0.95)  38 0.20 (0.92) 32 -0.09 (0.89)  17 0.15 (0.90) 19 -0.18 (0.97)  18 0.18 (1.06) 19 0.4 (1.38)  19 0.18 (1.06) 11 0.5 (-1, 1.5)  11 0.18 (1.06) 11 0.5 (-1, 1.5)  41 0.0 (1.03) 44 -0.14 (0.97)  35 0.2 (0.81) 32 0.09 (0.89)  36 0.0 (0.13) 32 0.09 (0.89)	Change from Bas	eline iı	n Condom Use Subject	ive No	rm		
38 0.20 (0.92) 32 0.09 (0.89) 0 (0.0, 0) 0 (0.0, 0) 1.7 0.15 (0.90) 19 0.18 (0.97) 0 (0.10, 0.1) 0 (0.10, 0.1) 0 (0.1, 0.5) 0 (0.1, 0.5) 1.1 0.18 (1.06) 1.1 0.5 (-1, 1.5) 0 (-1, 1.5) 0 (0.1, 0.5) 0 (0.0, 0.5) 0 (0	Immediate Post	43	0.03 (0.90) 0 (0, 0.5)	47	-0.15 (0.95)  0 $(-0.5, 0.5)$	0.3225	0.01
17 0.15 (0.90) 19 -0.18 (0.97) 0 (0.0) 0 (-1, 0.5)  11 0.18 (1.06) 11 0.14 (1.38)  12 0.0 (-1, 1) 0.5 (-1, 1.5)  41 0.0 (1.03) 44 0.05 (0.5)  35 0.2 (0.81) 32 0.09 (0.89)  36 0.0 (0.1) 32 0.00 (0.85)	3 Months	38	0.20 (0.92) 0 (0, 0)	32	-0.09 (0.89) $0 (-0.5, 0.5)$	0.6821	0.002
11 0.18 (1.06) 11 0.14 (1.38) 0 (-1, 1) 0.5 (-1, 1.5) 41 0.0 (1.03) 44 0.04 (0.97) 42 0.2 (0.81) 32 0.09 (0.89) 0 (0.1) 32 0.00 (0.89)	6 Months	17	0.15 (0.90) 0 (0, 0)	19	-0.18 (0.97) $0 (-1, 0.5)$	0.2548	0.04
41 0.0 (1.03) 44 0.04 (0.97) 0.0 (0.05, 0.5) 35 0.2 (0.01) 32 0.00 (0.89) 0.00 (0.05, 0.5)	12 Months	Ξ	0.18 (1.06) $0 (-1, 1)$	11	0.14 (1.38) 0.5 (-1, 1.5)	0.9472	<0.001
41 $0.0 (1.03)$ 44 $-0.14 (0.97)$ 0 (-0.5, 0.5) 44 $0 (-0.5, 0.5)35 0.2 (0.81) 32 -0.09 (0.89)0.0 (0.1)$ 32 $0.0 (-0.5, 0.5)$	Change from Bas	eline ii	n Condom Use Technic	al Skil	ls		
35 0.2 (0.81) 32 -0.09 (0.89) 0.00.1) 32 0.0 (-0.5.05)	Immediate Post	41	0.0 (1.03) 0 (-0.5, 0.5)	4	$-0.14\ (0.97)$ 0 (-0.5, 0.5)	0.5131	0.01
	3 Months	35	0.2 (0.81) 0 (0, 1)	32	-0.09 (0.89) $0.0 (-0.5, 0.5)$	0.2420	0.02

	AII.	HIV Intervention (N=52)	Ger	General Health (N=56)		
	u	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
6 Months	17	0.24 (0.79) 0.5 (0, 0.5)	18	-0.03 (0.88) 0 (-0.5, 0)	0.1529	0.06
12 Months	11	0.18 (0.51) 0 (0, 0.5)	10	-0.15 (0.97)  0 $(-1, 0)$	0.1492	0.10
Change from Bass	eline in	Change from Baseline in Condom Knowledge				
6 Months	17	0.14 (0.32) 0.2 (0, 0.20)	18	0.13 (0.31) 0 (0, 0.20)	0.6864	0.01
12 Months	11	0.05 (0.27) 0 (-0.2, 0.20)	12	0.12 (0.45) 0.20 (0, 0.20)	0.1978	0.07
Change from Base	line in	Change from Baseline in Anger Inhibition Scale	e			
Immediate Post	45	0.05 (0.60) 0 (-0.25, 0.5)	49	0.10 (0.49) 0.25 (-0.25, 0.5)	0.6647	0.002
3 Months	38	-0.01 (0.68) $0 (-0.5, 0.5)$	33	0 (0.52) 0.0 (-0.25, 0.25)	0.9212	<0.001
6 Months	17	0.18 (0.56) 0.25 (-0.25, 0.5)	20	0.04 (0.47) 0.13 (-0.25, 0.25)	0.4959	0.01
12 Months	11	0.09 (0.82) -0.25 (-0.25, 0.5)	12	0.10 (0.60) 0.25 (-0.25, 0.5)	0.6834	0.01
Change from Bass	line in	Change from Baseline in Anger Dysregulation Scale	Scale			
Immediate Post	46	0.04 (0.61) 0 (-0.33, 0.33)	49	0.10 (0.48) 0 (0, 0.33)	0.7143	0.001
3 Months	37	-0.08 (0.58) $0 (-0.33, 0.33)$	33	0.09 (0.43) 0 (0, 0.33)	0.1064	0.04
6 Months	17	0.02 (0.48) 0 (-0.33, 0.33)	20	0.02 (0.46) 0 (-0.33, 0.33)	0.9630	<0.001
12 Months	Ξ	0.18 (0.92) 0 (-0.67, 0.67)	12	0 (0.53) 0 (-0.33, 0.33)	0.8771	0.001
Change from Baseline in	line in	1 Anger Coping Scale				
Immediate Post	46	0.01 (0.47) 0 (-0.25, 0.25)	49	0.07 (0.36) 0 (-0.25, 0.25)	0.4386	0.01
3 Months	38	0.07 (0.47) 0 (-0.25, 0.5)	33	0.02 (0.38) 0 (-0.25, 0.25)	0.7103	0.002
6 Months	17	0.28 (0.4) 0.5 (0, 0.5)	18	0.06 (0.48) 0.13 (-0.25, 0.25)	0.1458	90.0
12 Months	11	-0.16 (0.39) -0.25 (-0.5, 0.25)	12	0.06 (0.37) 0 (-0.25, 0.38)	0.1148	0.11

Change facin Dec	¤	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
Change Ironi baseinie in	eline ir	Sadness Inhibition Scale	cale			
Immediate Post	4	-0.02 (0.57) $0 (-0.25, 0.25)$	4	0.08 (0.60) 0 (-0.25, 0.38)	0.3965	0.01
3 Months	38	0.11 (0.64) 0 (-0.25, 0.5)	33	-0.03 (0.48) 0 (-0.25, 0.25)	0.4629	0.01
6 Months	17	0.07 (0.65) 0 (-0.25, 0.25)	19	-0.01 (0.52) 0 (-0.5, 0.25)	0.7722	0.002
12 Months	11	0.09 (0.63) 0 (-0.5, 0.5)	12	0.17 (0.75) 0.13 (-0.5, 0.88)	0.8039	0.003
Change from Bas	eline ir	Change from Baseline in Sadness Dysregulation Scale	on Scale			
Immediate Post	4	0.17 (0.54) 0 (-0.33, 0.33)	44	0.27 (0.65) 0.33 (0, 0.67)	0.1913	0.02
3 Months	37	0.17 (0.51) 0 (0, 0.33)	33	0.14 (0.53) 0 (0, 0.67)	0.9855	<0.001
6 Months	17	0.16(0.5) 0(-0.33, 0.67)	18	0.15 (0.51) 0 (0, 0.67)	0.8646	0.001
12 Months	==	$0.55 (0.65) \\ 0.67 (0, 1)$	12	0.11 (0.64) 0 (0, 0.5)	0.2304	90.0
Change from Bas	eline ir	Change from Baseline in Sadness Coping Scale	မ			
Immediate Post	4	0.06 (0.52) 0 (-0.2, 0.4)	42	0 (0.51) 0 (-0.2, 0.4)	0.6859	0.002
3 Months	37	0.08 (0.56) 0 (-0.2, 0.4)	32	0 (0.42) 0 (-0.2, 0.4)	0.6020	0.004
6 Months	17	0.32 (0.58) 0.20 (-0.2, 0.8)	17	0.02 (0.48) -0.2 (-0.4, 0.6)	0.2254	0.04
12 Months	11	-0.02 (0.68) -0.2 (-0.6, 0.4)	12	0.17 (0.67) 0 (-0.4, 0.7)	0.5578	0.02
Change from Bas	eline ir	Change from Baseline in Pro-Black Ethnic Identity Score	ntity Sc	ore		
Immediate Post	45	0.13 (0.39) 0 (0, 0.29)	47	0.11 (0.48) 0.14 (0, 0.43)	0.4412	0.01
3 Months	38	0.10 (0.36) 0 (-0.14, 0.29)	32	0.04 (0.37) 0 (-0.14, 0.14)	0.6182	0.004
6 Months	16	0.11 (0.43) 0.14 (-0.07, 0.36)	20	0.14 (0.38) 0 (0, 0.29)	0.9356	<0.001
12 Months	11	0.14 (0.34) 0.14 (-0.14, 0.29)	12	0.23 (0.32) 0.14 (0, 0.43)	0.6874	0.01

	HIV	HIV Intervention (N=52)	Ger	General Health (N=56)		
	g	Mean (SD) or % Median (IQR)	п	Mean (SD) or % Median (IQR)	$\text{P-value}^I$	Effect Size <sup>2</sup>
Change from Bas	eline ir	Change from Baseline in Anti-White Ethnic Identity Score	lentity	Score		
Immediate Post	4	-0.07 (0.56) 0 (-0.25, 0.25)	4	-0.06 (0.51) 0 (-0.38, 0.25)	0.8953	<0.001
3 Months	36	0 (0.48) 0 (-0.25, 0.25)	27	0.03 (0.49) 0 (-0.25, 0.25)	0.8935	<0.001
6 Months	15	-0.25 (0.64) 0 (05 0.25)	17	$0.04 (0.48) \\ -0.25 (-0.25, 0.25)$	0.3480	0.03
12 Months	Ξ	-0.05 (0.6) 0 (-0.5, 0.5)	=	0.02 (0.43) 0 (-0.25, 0.25)	0.8155	0.002
Change from Bas	eline ir	Change from Baseline in Racism Awareness Ethnic Identity Score	thnic Io	dentity Score		
Immediate Post	42	0.07 (0.45)	43	0.01 (0.55) 0 (-0.2, 0.4)	0.9612	<0.001
3 Months	35	0.17 (0.5) $0.2 (-0.2, 0.4)$	31	0.19 (0.58) 0 (-0.2, 0.4)	0.6888	0.002
6 Months	16	-0.05 (0.51) 0 (-0.4, 0.2)	19	0.29 (0.6) 0.2 (0, 0.6)	0.1096	0.07
12 Months	11	0.02 (0.53) 0 (-0.4, 0.4)	12	0.07 (0.42) -0.1 (-0.2, 0.4)	0.9015	0.001
Change from Bas	eline ir	Change from Baseline in Attitudes Toward Women Score	men S	core		
Immediate Post	40	1 (0.64) 1 (0.67, 1.46)	41	0.86 (0.83) 0.75 (0.25, 1.25)	0.1536	0.03
3 Months	34	0.01 (0.29) 0 (-0.17, 0.25)	27	0 (0.25) -0.08 (-0.17, 0.17)	0.6104	0.004
6 Months	15	0.07 (0.36) 0.17 (-0.17, 0.42)	41	-0.04 (0.27) -0.08 (-0.25, 0.17)	0.4187	0.02
12 Months	10	0.17 (0.42) 0.17 (0, 0.33)	11	-0.04 (0.32) 0 (-0.25, 0.17)	0.2730	90.0
Change from Bas	eline ir	Change from Baseline in HIV/STD Knowledge Scale Score	e Scale	Score		
Immediate Post	45	0 (0.3) 0.06 (-0.17, 0.19)	45	-0.14 (0.26) -0.13 (-0.3, -0.02)	0.0011	0.12
3 Months	35	0.06 (0.16) 0.07 (-0.07, 0.14)	30	-0.05 (0.31) 0 $(-0.29, 0.21)$	0.2478	0.02
6 Months	17	0.07 (0.24)	18	0.06 (0.24)	0.4455	0.02

	HIIV	HIV Intervention (N=52)	Gen	General Health (N=56)		
	п	Mean (SD) or % Median (IQR)	u	Mean (SD) or % Median (IQR)	P-value	Effect Size <sup>2</sup>
12 Months	11	0.06 (0.16) 0.07 (0, 0.21)	12	0.09 (0.31) 0.14 (0.04, 0.21)	0.3534	0.04
Change from Baseline in PHQ-9 Score	eline i	n PHQ-9 Score				
Immediate Post	47	-1.06 (2.03) -1 (-2, 0)	51	0.10 (2.45) 0 (-1, 2)	0.0070	0.07
3 Months	38	-0.37 (2.52) 0 (-2, 0)	33	1.42 (4.93) 0 (0, 2)	0.0480	0.06
6 Months	17	-1.06 (3.77) -2 (-3, 0)	22	$0 (3.53) \\ 0 (-2, 1)$	0.1582	0.05
12 Months	Π	-0.27 (4.45) -2 (-3, 1)	13	0.08 (3.20) 0 (-1, 1)	0.4305	0.03

Note: SD=standard deviation; IQR=interquartile range

P-values are based on non-parametric exact Wilcoxon rank-sum tests for continuous variables and Fisher's exact tests for categorical variables

2 Effect sizes are based on  $\eta^2$  (eta-squared) for continuous variables (small: 0.01, medium: 0.06, large: >0.14) and Cramer's V for categorical variables (small: 0.10-0.29, medium: 0.30-0.50, large: >0.50).